[go: up one dir, main page]

KR101818816B1 - Method for Producing and Purifying Virus-Like Particle of Rotavirus using Yeast strain - Google Patents

Method for Producing and Purifying Virus-Like Particle of Rotavirus using Yeast strain Download PDF

Info

Publication number
KR101818816B1
KR101818816B1 KR1020150136207A KR20150136207A KR101818816B1 KR 101818816 B1 KR101818816 B1 KR 101818816B1 KR 1020150136207 A KR1020150136207 A KR 1020150136207A KR 20150136207 A KR20150136207 A KR 20150136207A KR 101818816 B1 KR101818816 B1 KR 101818816B1
Authority
KR
South Korea
Prior art keywords
rotavirus
virus
particles
present
cau200
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020150136207A
Other languages
Korean (ko)
Other versions
KR20170037708A (en
Inventor
김원용
김성근
김예나
Original Assignee
중앙대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 중앙대학교 산학협력단 filed Critical 중앙대학교 산학협력단
Priority to KR1020150136207A priority Critical patent/KR101818816B1/en
Publication of KR20170037708A publication Critical patent/KR20170037708A/en
Application granted granted Critical
Publication of KR101818816B1 publication Critical patent/KR101818816B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08RNA viruses
    • C07K14/14Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/15Reoviridae, e.g. calf diarrhea virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/12011Reoviridae
    • C12N2720/12311Rotavirus, e.g. rotavirus A
    • C12N2720/12323Virus like particles [VLP]
    • C12R1/84

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

본 발명은 효모 세포주를 이용한 로타바이러스의 바이러스 유사입자 생산 방법 및 정제 방법에 관한 것이다.
본 발명에서는, 효모 기반 체계에서 로타바이러스의 주요 구조 단백질(VP2, VP6, VP7)을 동시에 발현시킴으로써 삼중층의 자가-조립된 바이러스 유사 입자를 생산하였으며, 발현 유도 조건을 최적화하여 상기 재조합 단백질들의 발현양을 증대시켰을 뿐만 아니라, 재조합 단백질들의 용해도를 높일 수 있는 세포파쇄 완충액(Cell lysis buffer)의 조성 변화에 따른 우수한 정제 효율을 확인하였는바, 로타바이러스 감염증의 예방 및 치료에 다양하게 이용될 수 있을 것으로 기대된다.
The present invention relates to a method for producing virus-like particles of rotavirus using a yeast cell line and a purification method thereof.
In the present invention, self-assembled virus-like particles of a triple layer were produced by simultaneously expressing major structural proteins (VP2, VP6, VP7) of rotavirus in a yeast-based system, and the expression of the recombinant proteins The present inventors have confirmed the excellent purification efficiency according to the compositional change of the cell lysis buffer which can increase the solubility of the recombinant proteins and can be used variously for prevention and treatment of rotavirus infection .

Description

효모 세포주를 이용한 로타바이러스의 바이러스 유사입자 생산 및 정제 방법 {Method for Producing and Purifying Virus-Like Particle of Rotavirus using Yeast strain}FIELD OF THE INVENTION [0001] The present invention relates to a method for producing virus-like particles of rotavirus using a yeast cell line,

본 발명은 효모 세포주를 이용한 로타바이러스의 바이러스 유사입자 생산 및 정제방법에 관한 것이다.The present invention relates to a method for producing and purifying virus-like particles of rotavirus using a yeast cell line.

로타바이러스(Human Rotavirus, HRV)는 영유아에서 설사를 유발하는 주요 바이러스로서 한국을 비롯해 전 세계의 5세 이하 소아 95%가 적어도 한 번 이상 감염되며, 전 세계적으로 매년 발생하는 설사 환자의 약 40%를 차지하는 것으로 알려져 있다. 또한, 미국 질병관리본부(CDC)의 보고에 따르면 로타바이러스 설사증으로 미국에서 소요되는 의료비만도 1년에 1천만 달러에 달하며, 국내의 경우 급성 장염으로 입원하는 영유아 환자의 70%가 로타바이러스 감염에 기인하는 것으로 알려져 있다. 따라서 세계보건기구(WHO)는 개발도상국에서는 로타바이러스 발생을 감소시키고 선진국에서는 의료비의 절감을 목표로 로타바이러스에 대한 백신 개발을 최우선 과제로 삼고 있는 실정이다.Human Rotavirus (HRV) is a major virus causing infantile diarrhea in infants and young children. It accounts for at least 40% of the world's diarrheal diseases every year, Respectively. According to a report by the US Centers for Disease Control and Prevention (CDC), rotavirus diarrhea is estimated to cost $ 10 million a year in the US, and 70% of infants and children with acute enteritis are receiving rotavirus infection . Therefore, the World Health Organization (WHO) has been developing vaccines against rotavirus as a top priority in developing countries to reduce the incidence of rotavirus and to reduce medical costs in developed countries.

로타바이러스는 피막이 없고, 직경 75nm의 정 20면체 형태로 외부 캡시드(outer capsid), 내부 캡시드(inner capsid), 코어 단백질(core protein)의 3중층 단백질 캡시드(triple layered protein capsid)로 구성되어 있으며, 11개의 분절로 구성되어 있다. 각각의 분절은 6개의 구조 단백질(VP1, VP2, VP3, VP4, VP6, VP7)과 6개의 비구조 단백질(NSP 1-6) 중 하나를 암호화하고 있다. 로타바이러스는 VP6의 항원성에 따라 A군으로부터 G군까지 7개군으로 분류되고, 전 세계적으로 가장 흔한 A군은 다시 면역원성 단백인 VP7에 의한 G형(Glycoprotein type)과 VP4에 의한 P형(Protease-sensitive type)으로 세분될 수 있으며, 현재 23종의 G형과 32종의 P형이 보고되어 있다. 사람에서는 G1-G4, G6, G8-G10과 G12 등 9개 혈청형과 P[3], P[4], P[6], P[8]-P[11]과 P[14] 등 8개 유전자형이 감염을 일으키며 각 혈청형들은 서로 교차방어가 되지 않는 특징이 있다.Rotavirus has no coating and consists of a triple layered protein capsid of outer capsid, inner capsid and core protein in the form of a regular icosahedral with a diameter of 75 nm. It consists of 11 segments. Each segment encodes one of six structural proteins (VP1, VP2, VP3, VP4, VP6, VP7) and six nonstructural proteins (NSP 1-6). Rotavirus is classified into 7 groups according to the antigenicity of VP6. Group A, which is the most common group in the world, is divided into G type (Glycoprotein type) by VP7, immunological protein, and P type -sensitive type). Currently, 23 types of G-type and 32 types of P-type are reported. In humans, nine serotypes such as G1-G4, G6, G8-G10 and G12 and P [3], P [4], P [6], P [8] The genotypes are infectious, and each serotype is not cross - protective.

모든 혈청형간 교차 방어가 되지 않는 로타바이러스의 특징으로 인하여 각 혈청형에 대한 감염을 보호할 수 있는 효과적인 로타바이러스 백신의 개발이 요구되어 왔다. 현재까지 경구용 약독화 생백신과 동물-사람 재조합 백신을 사용하였으나 다른 혈청형의 감염에 대하여 충분한 방어능을 보여주지 못하고 있다, 미국 와이어스-아이어스트(Wyeth-Ayerst)사에서 개발한 Rotashield는 발생률이 가장 높은 G혈청형(G1~G4)을 혼합한 4가 약독화 생백신으로 FDA 승인을 받아 기본 접종에 포함되었으나 장 중첩 환자가 발생하여 사용이 중단된 상태이다. 이에, 새로운 백신의 소재로서 바이러스 유사입자(VLP)에 대한 관심이 증대되고 있으며, 다양한 연구가 이루어 지고 있다. 현재, 대장균(Escherichia coli) 발현 시스템 또는 곤충세포를 이용한 배큘로바이러스(Baculovirus) 발현 시스템이 주로 이용되고 있으나, 대장균 등의 원핵세포 발현계에서는 내독소를 가지고 있으며, 자연형과 유사한 바이러스 단백질 입자를 생산하기 어려워 항원성을 제대로 나타내지 못하며, 곤충세포를 이용한 경우에는 배양과정 중 오염 위험과 정제의 어려움 및 높은 생산비용과 낮은 수율로 인해 만족할 만한 생산 효과를 얻지 못하는바, 로타바이러스 백신으로 활용함에 있어서 한계가 있었다. Due to the characteristics of rotavirus that does not cross-protect all serotypes, the development of an effective rotavirus vaccine capable of protecting infections against each serotype has been required. To date, oral live attenuated vaccines and animal-human recombinant vaccines have been used but have not shown adequate protection against other serotype infections. Rotashield, developed by Wyeth-Ayerst, USA, It is a 4-valent live attenuated vaccine containing the highest G serotype (G1 to G4) and has been approved by the Food and Drug Administration (FDA). Accordingly, interest in virus-like particles (VLPs) as a new vaccine material has been increasing, and various studies have been made. At present, Escherichia coli expression system or baculovirus expression system using insect cells is mainly used. However, prokaryotic cell expression systems such as Escherichia coli have endotoxin, In case of using insect cells, it is not possible to obtain a satisfactory production effect due to the risk of contamination during the culturing process, difficulty of purification, high production cost, and low yield, and in the application to rotavirus vaccine There was a limit.

이에, 바이러스 유사입자(VLP)를 안정적이면서 효율적으로 생산하기 위한 방법에 대한 연구가 이루어지고 있으나(한국 특허공개번호 10-2015-0045191), 아직은 미비한 실정이다. Thus, a method for stably and efficiently producing virus-like particles (VLP) has been studied (Korean Patent Laid-open Publication No. 10-2015-0045191).

본 발명은 상기와 같은 문제점을 해결하기 위해 안출된 것으로서, 본 발명자들은 효모 기반 체계에서 로타바이러스의 바이러스 구조 단백질인 VP2, VP6, VP7을 동시에 발현시킨 바이러스 유사입자를 생산하였다. 또한, 로타바이러스의 바이러스 유사입자 생산 공정에서, 생산 수율을 증가시킬 수 있는 배양 및 정제 조건에 대해 연구한 결과, 발현 유도 조건 변화에 따른 단백질 발현량 증대 및 세포파쇄 완충액 조성 변화에 따른 정제 효율 증진 효과를 확인하고, 이에 기초하여 본 발명을 완성하게 되었다.Disclosure of the Invention The present invention was conceived to solve the above problems, and the present inventors produced viral-like particles simultaneously expressing virus structural proteins VP2, VP6 and VP7 of rotavirus in a yeast-based system. In addition, as a result of studying the culture and purification conditions that can increase the production yield in the virus-like particle production process of rotavirus, it was found that the increase of the protein expression amount and the purification efficiency according to the composition of the cell disruption buffer And the present invention has been completed on the basis thereof.

이에, 본 발명의 목적은 a) 로타바이러스 구조 단백질이 발현되도록 효모 세포를 형질전환하는 단계; b) 상기 형질전환된 효모 세포를 메탄올이 첨가된 배지에서 배양하는 단계; c) 상기 배양된 효모 세포를 용해시켜 세포 용해물을 얻는 단계; 및 d) 상기 세포 용해물로부터 로타바이러스의 바이러스 유사입자를 분리 및 정제하는 단계 포함하는 로타바이러스(Rotavirus)의 바이러스 유사입자(virus-like particle, VLP)의 생산 및 정제방법을 제공하는 것이다.Accordingly, an object of the present invention is to provide a method for producing a rotavirus structural protein, comprising the steps of: a) transforming a yeast cell to express a rotavirus structural protein; b) culturing the transfected yeast cells in a medium supplemented with methanol; c) dissolving the cultured yeast cells to obtain a cell lysate; And d) separating and purifying virus-like particles of rotavirus from the cell lysate. The present invention also provides a method for producing and purifying virus-like particles (VLP) of Rotavirus.

또한, 본 발명의 다른 목적은 상기 방법에 의해 생산 및 정제된 로타바이러스의 바이러스 유사입자를 제공하는 것이다.Another object of the present invention is to provide virus-like particles of rotavirus produced and purified by the above method.

또한, 본 발명의 또 다른 목적은 상기 로타바이러스의 바이러스 유사입자를 포함하는, 면역원성 조성물을 제공하는 것이다.Still another object of the present invention is to provide an immunogenic composition comprising virus-like particles of the rotavirus.

그러나 본 발명이 이루고자 하는 기술적 과제는 이상에서 언급한 과제에 제한되지 않으며, 언급되지 않은 또 다른 과제들은 아래의 기재로부터 당업자에게 명확하게 이해될 수 있을 것이다.However, the technical problem to be solved by the present invention is not limited to the above-mentioned problems, and other matters not mentioned can be clearly understood by those skilled in the art from the following description.

상기와 같은 본 발명의 목적을 달성하기 위하여, 본 발명은 a) 로타바이러스 구조 단백질이 발현되도록 효모 세포를 형질전환하는 단계; b) 상기 형질전환된 효모 세포를 메탄올이 첨가된 배지에서 배양하는 단계; c) 상기 배양된 효모 세포를 용해시켜 세포 용해물을 얻는 단계; 및 d) 상기 세포 용해물로부터 로타바이러스의 바이러스 유사입자를 분리 및 정제하는 단계 포함하는 로타바이러스(Rotavirus)의 바이러스 유사입자(virus-like particle, VLP)의 생산 및 정제방법을 제공한다.In order to accomplish the above object, the present invention provides a method for producing a rotavirus structural protein, comprising the steps of: a) transforming a yeast cell to express a rotavirus structural protein; b) culturing the transfected yeast cells in a medium supplemented with methanol; c) dissolving the cultured yeast cells to obtain a cell lysate; And d) separating and purifying virus-like particles of rotavirus from the cell lysate. The present invention also provides a method for producing and purifying virus-like particles (VLP) of Rotavirus.

본 발명의 일 구현예로서, 상기 단계 a)는 서열번호 1로 표시되는 pPIC6-CAU200 VP2 벡터, 서열번호 2로 표시되는 pPICZ-CAU200 VP6 벡터, 및 서열번호 3으로 표시되는 pPIC3.5K-CAU200 VP7 벡터로 효모 세포를 형질전환할 수 있다.In one embodiment of the present invention, the step a) comprises the steps of: a pPIC6-CAU200 VP2 vector of SEQ ID NO: 1; a pPICZ-CAU200 VP6 vector of SEQ ID NO: 2; and a pPIC3.5K-CAU200 VP7 Yeast cells can be transformed into vectors.

본 발명의 다른 구현예로서, 상기 단계 a)에서의 효모는 피키아 파스토리스(Pichia pastoris)일 수 있다. In another embodiment of the present invention, the yeast in step a) may be Pichia pastoris .

본 발명의 또 다른 구현예로서, 상기 단계 b)는 0.5 내지 1.5% 농도의 메탄올을 첨가하여 24 내지 96시간 배양할 수 있다. In another embodiment of the present invention, the step (b) may be carried out by adding methanol at a concentration of 0.5 to 1.5% for 24 to 96 hours.

본 발명의 또 다른 구현예로서, 상기 단계 b)는 1 내지 1.5% 농도의 메탄올을 첨가하여 24 내지 48시간 배양할 수 있다. In another embodiment of the present invention, the step b) may be carried out by adding methanol at a concentration of 1 to 1.5% for 24 to 48 hours.

본 발명의 또 다른 구현예로서, 상기 단계 c)는 Tris-HCl, NaCl, CaCl2, EDTA, PMSF, glycerol, 및 Tween20을 함유하는 세포파쇄 완충액으로 용해시킬 수 있다. As a further embodiment, the step c) may be dissolved in cell disruption buffer containing Tris-HCl, NaCl, CaCl 2 , EDTA, PMSF, glycerol, and Tween20.

본 발명은 상기 방법에 의해 생산 및 정제된 로타바이러스의 바이러스 유사입자를 제공한다. The present invention provides virus-like particles of rotavirus produced and purified by the above method.

본 발명의 일 구현예로서, 상기 바이러스 유사입자는 로타바이러스 구조 단백질인 VP2, VP6, 및 VP7을 동시에 발현할 수 있다.In one embodiment of the present invention, the virus-like particle can simultaneously express the rotavirus structural proteins VP2, VP6, and VP7.

본 발명은 상기 로타바이러스의 바이러스 유사입자를 포함하는, 면역원성 조성물을 제공한다.The present invention provides an immunogenic composition comprising virus-like particles of said rotavirus.

본 발명은 상기 로타바이러스의 바이러스 유사입자를 개체에 투여하는 단계를 포함하는 로타바이러스 감염증 예방 또는 치료방법을 제공한다.The present invention provides a method for preventing or treating rotavirus infection comprising administering the virus-like particles of the rotavirus to a subject.

본 발명은 로타바이러스의 바이러스 유사입자의 로타바이러스 감염증 예방 또는 치료용도를 제공한다.The present invention provides a method for preventing or treating rotavirus infection of virus-like particles of rotavirus.

본 발명에 따르면, 효모 기반 체계에서 로타바이러스의 구조 단백질인 VP2, VP6, 및 VP7을 동시에 발현시킴으로써 삼중층의 자가-조립된 바이러스 유사 입자를 생산하였으며, 발현 유도 조건을 최적화하여 상기 재조합 단백질들의 발현양을 증대시켰을 뿐만 아니라, 재조합 단백질들의 용해도를 높일 수 있는 특정 세포파쇄 완충액(Cell lysis buffer)을 이용함으로써 정제 효율을 증진시킬 수 있었다. 이에, 본 발명은 바이러스 유사입자의 제조에 있어서, 종래부터 지적되어왔던 낮은 수율 및 높은 생산 비용에 대한 문제점을 해소한 것으로 로타바이러스에 대한 신규 백신의 연구 및 개발에 효과적으로 활용될 수 있을 것으로 기대된다. According to the present invention, self-assembled virus-like particles of a triple layer were produced by simultaneously expressing the structural proteins VP2, VP6, and VP7 of the rotavirus in the yeast-based system, and the expression of the recombinant proteins In addition, the purification efficiency could be improved by using a cell lysis buffer that can increase the solubility of the recombinant proteins. Accordingly, the present invention solves the problem of low yield and high production cost, which have been pointed out in the production of virus-like particles, and is expected to be effectively utilized in the research and development of new vaccines against rotavirus .

도 1은 로타바이러스(Rotavirus) 감염 환자로부터 분리한 인간 로타바이러스 구조 단백질 유전자(VP2, VP6, VP7)들이 피키아 파스토리스(Pichia pastoris)에서 동시에 발현될 수 있도록 형질전환시키는 과정을 개략적으로 나타낸 도이다.
도 2는 인간 로타바이러스 구조 단백질 유전자(VP2, VP6, VP7)가 모두 형질전환된 피키아 파스토리스 콜로니를 AOX1 프라이머와 각 유전자(VP2, VP6, VP7) 특이적 프라이머를 사용하여 콜로니 PCR을 한 결과이다(M 레인은 1kb DNA 크기 마커, 1번 레인은 universal AOX1 프라이머, VP2 특이 프라이머, 2번 레인은 VP6 특이 프라이머, 3번 레인은 VP7 특이 프라이머를 통해 확인한 결과이다.).
도 3a는 쥐의 단일클론 항-His 항체를 사용하여, 상층액 내 로타바이러스 구조 단백질(VP2, VP6, VP7)의 발현을 웨스턴 블로팅을 통해 확인한 결과이다(1번 레인은 피키아 파스토리스 음성대조군, 2번 레인은 재조합 VP2, 3번 레인은 재조합 VP6, 4번 레인은 재조합 VP7, 5번 레인은 VP2/VP6/VP7이 모두 발현된 군, M 레인은 Thermo Scientific Spectra Multicolor Broad Range Protein Ladder을 나타낸다.).
도 3b는 토끼의 다클론 로타바이러스 Wa 항혈청를 사용하여, 상층액 내 로타바이러스 구조 단백질(VP2, VP6, VP7)의 발현을 웨스턴 블로팅을 통해 확인한 결과이다(1번 레인은 피키아 파스토리스 음성대조군, 2번 레인은 재조합 VP2, 3번 레인은 재조합 VP6, 4번 레인은 재조합 VP7, 5번 레인은 VP2/VP6/VP7이 모두 발현된 군, M 레인은 Thermo Scientific Spectra Multicolor Broad Range Protein Ladder을 나타낸다.).
도 4는 정제된 로타바이러스의 바이러스 유사입자를 투과전자현미경으로 관찰한 결과이다.
도 5는 재조합 로타바이러스의 바이러스 유사입자의의 면역원성을 확인하기위하여 로타바이러스 Wa 항원에 대한 쥐 면역혈청의 항체가를 측정한 결과이다((□)는 음성대조군으로서 아무런 주사도 하지 않은 쥐 혈청의 항체가, (○)은 음성대조군으로서 항원을 섞지 않은 adjuvant만을 주사한 쥐 혈청의 항체가, (■)은 재조합 항원 로타바이러스 VLP의 쥐 면역혈청의 항체가를 나타낸 것으로서, 오차막대는 5마리의 쥐로 실험한 표준편차를 나타낸다.).
도 6은 첨가된 메탄올의 농도 및 발현 유도 시간에 따른 로타바이러스 구조 단백질의 발현양을 비교하기 위하여 웨스턴 블로팅을 통해 각 재조합 단백질들의 발현 정도를 측정하고 Image J 프로그램을 통해 정량화한 결과이다.
도 7은 세포 파쇄 완충액의 차이에 따른 상층액 단백질의 단백질 용해성(solubility)을 비교하기 위하여 각 재조합 단백질들의 발현 정도를 측정하고 Image J 프로그램을 통해 정량화한 결과이다.
1 schematically shows a process of transforming human rotavirus structural protein genes (VP2, VP6, VP7) isolated from patients suffering from Rotavirus infection so that they can be simultaneously expressed in Pichia pastoris to be.
FIG. 2 shows the results of colony PCR using AOX1 primer and primers specific for each gene (VP2, VP6, and VP7) for the Pichia pastoris colony transformed with all of the human rotavirus structural protein genes (VP2, VP6 and VP7) (M lane is a 1kb DNA size marker, lane 1 is a universal AOX1 primer, VP2 specific primer, lane 2 is a VP6 specific primer, and lane 3 is a VP7 specific primer).
Figure 3a shows the results of western blotting of expression of rotavirus structural proteins (VP2, VP6, VP7) in the supernatant using rat monoclonal anti-His antibodies (lane 1 shows the expression of Pichia pastoris negative In the control, the lane 2 was recombinant VP2, the lane 3 was recombinant VP6, the lane 4 was recombinant VP7, the lane 5 was expressed VP2 / VP6 / VP7 and the lane was a Thermo Scientific Spectra Multicolor Broad Range Protein Ladder ).
Figure 3b shows the results of western blotting of expression of rotavirus structural proteins (VP2, VP6, VP7) in the supernatant using polyclonal rotavirus Wa antiserum of rabbits (lane 1 is the Pichia pastoris negative control , Recombinant VP2 in lane 2, recombinant VP6 in lane 3, recombinant VP7 in lane 4, VP2 / VP6 / VP7 in lane 5 and M lane in Thermo Scientific Spectra Multicolor Broad Range Protein Ladder .).
FIG. 4 shows the result of observing virus-like particles of purified rotavirus with a transmission electron microscope.
FIG. 5 shows the result of measuring antibody titers of mouse immunity sera against rotavirus Wa antigen to confirm the immunogenicity of virus-like particles of recombinant rotavirus (() Of the recombinant antigen rotavirus VLP antibody, and (o) is the antibody of the rat serum injected only with the adjuvant not mixed with the antigen as the negative control, (5) represents the antibody value of the mouse immunized serum of the recombinant antigen rotavirus VLP, Of the mice tested).
FIG. 6 shows the results of Western blotting to determine the expression level of rotavirus structural proteins according to the concentration of methanol added and the induction time of the added methanol, and quantification of the expression level of each recombinant protein using the Image J program.
FIG. 7 shows the results of measurement of the degree of expression of each recombinant protein and quantification using an Image J program in order to compare the solubility of the protein in the supernatant protein according to the difference in the cell disruption buffer.

본 발명자들은, 발현 균주로 피키아 파스토리스(Pichia pastoris)를 이용하여, 로타바이러스의 구조 단백질인 VP2, VP6, 및 VP7이 발현된 바이러스 유사 입자를 생산하였으며, 상기 바이러스 유사 입자의 우수한 면역원성을 확인하였다. 또한, 메탄올 농도 및 발현 유도 시간에 따른 로타바이러스 구조 단백질 발현양 증가 및 세포 파쇄 완충액에 따른 상층액 단백질의 용해성 차이를 확인하고, 이에 기초하여 본 발명을 완성하였다.The present inventors produced virus-like particles expressing VP2, VP6, and VP7, which are structural proteins of rotavirus, using Pichia pastoris as an expression strain, and found that the excellent immunogenicity of the virus-like particles Respectively. In addition, the present inventors completed the present invention on the basis of the increase in the amount of rotavirus structural protein expression and the difference in solubility of the supernatant protein depending on the methanol concentration and induction time.

이에, 본 발명은 하기의 단계를 포함하는 로타바이러스(Rotavirus)의 바이러스 유사입자(virus-like particle, VLP)의 생산 및 정제방법을 제공한다.Accordingly, the present invention provides a method for producing and purifying virus-like particles (VLPs) of Rotavirus comprising the following steps.

a) 로타바이러스 구조 단백질이 발현되도록 효모 세포를 형질전환하는 단계;a) transforming yeast cells to express a rotavirus structural protein;

b) 상기 형질전환된 효모 세포를 메탄올이 첨가된 배지에서 배양하는 단계;b) culturing the transfected yeast cells in a medium supplemented with methanol;

c) 상기 배양된 효모 세포를 용해시켜 세포 용해물을 얻는 단계; 및c) dissolving the cultured yeast cells to obtain a cell lysate; And

d) 상기 세포 용해물로부터 로타바이러스의 바이러스 유사입자를 분리 및 정제하는 단계. d) separating and purifying virus-like particles of rotavirus from the cell lysate.

본 발명의 바이러스 유사입자의 생산 및 정제방법에 따르면, 로타바이러스의 바이러스 구조 단백질인 VP2, VP6, VP7을 효모 세포에 동시에 발현시킬 수 있으며, 메탄올 농도, 발현 유도 시간, 세포 파쇄 완충액의 조성을 조절함으로써, 바이러스 유사입자의 생산 효율을 극대화하였는바, 로타바이러스에 대한 신규 백신의 연구 및 개발에 효과적으로 활용될 수 있을 것으로 기대된다. According to the method for producing and purifying virus-like particles of the present invention, virus structural proteins VP2, VP6 and VP7 of rotavirus can be simultaneously expressed in yeast cells, and the concentration of methanol, the induction time and the composition of cell- , Maximizing the production efficiency of virus-like particles, and is expected to be effectively utilized in research and development of new vaccines against rotavirus.

이하에서는, 본 발명에 따른 바이러스 유사입자의 생산 및 정제방법의 각각 단계에 대하여 상세히 설명하기로 한다.Hereinafter, each step of the method for producing and purifying virus-like particles according to the present invention will be described in detail.

단계 a)에서는, 로타바이러스 구조 단백질이 발현되도록 효모 세포를 형질전환한다. In step a), the yeast cells are transformed to express the rotavirus structural protein.

본 발명에서, '로타바이러스(Rotavirus)'는 직경 70mm의 reoviridae과에 속하는 이중 나선형의 RNA바이러스로서, genome은 11개의 유전자 분절로 구성되어 있으며, 핵은 이중 capsid로 둘러싸여 있다. 현재까지 6가지 이상의 구조 단백질과 4가지의 비구조 단백질이 알려져 있다. Inner capsid에 4종류의 구조 단백질(VP1, VP2, VP3, VP6)이 있으며, outer capsid에 2종류의 구조 단백질(VP4, VP7)이 있다. Rotavirus는 outer capsid가 없는 rough particle과 outer capsid가 있는 smooth particle의 형태로 존재하는데, outer capsid에만 숙주 세포막의 특이 수용체에 결합하는 구조 단백질 VP4, VP7이 있으므로 smooth particle만이 감염을 일으킬 수 있다고 알려져 있다. 또한, 현재까지 사람에서 7 가지의 혈청형이 분리되었으며, 특히 1형과 3형에 의한 감염이 가장 흔한 것으로 알려져 있다. 로타바이러스는 모든 혈청형간 교차 방어가 되지 않으므로 각각의 혈청형에 대한 감염에 대해 보호할 수 있는 효과적인 로타바이러스 백신의 개발이 필요한 실정이다. 이에, 본 발명에서는, 로타바이러스의 주요 구조 단백질의 동시 발현 및 자가 조립 기능을 통해 원래의 바이러스와 유사한 형태를 갖는 바이러스 유사입자를 제조하였고, 각각의 혈청형으로 유전자 교체 발현 혹은 동시 발현이 용이하도록 시스템을 구축하였다. 구체적으로는, 로타바이러스 구조 단백질인 VP2, VP6 및 VP7이 동시에 발현된 삼중층의 바이러스 유사입자를 생산하였으며, 자연적인 감염성 로타바이러스와 유사하여 항원 구조를 유지한 채로 체내의 면역세포에 제시되어 효율적으로 면역반응을 유도할 수 있을 뿐만 아니라, 바이러스 증식에 필요한 바이러스의 유전자를 포함하고 있지 않아 병원성이 없다는 장점이 있다. In the present invention, 'Rotavirus' is a double helical RNA virus belonging to reoviridae having a diameter of 70 mm. The genome is composed of 11 gene segments, and the nucleus is surrounded by double capsid. To date, more than six structural proteins and four non-structural proteins have been known. There are four structural proteins (VP1, VP2, VP3, VP6) in the inner capsid and two structural proteins (VP4, VP7) in the outer capsid. Rotavirus is present in the form of rough particles with no outer capsids and smooth particles with outer capsids. Only outer particles are known to cause infection because smooth proteins are the structural proteins VP4 and VP7 that bind to specific receptors on the host cell membrane. In addition, up to now, seven serotypes have been isolated from humans, and infection by type 1 and type 3 is the most common. Because rotavirus does not cross-protect against all serotypes, it is necessary to develop an effective rotavirus vaccine that can protect against infection with each serotype. Thus, in the present invention, viral-like particles having a shape similar to that of the original virus were produced through simultaneous expression and self-assembly function of the major structural proteins of rotavirus, and gene replacement expression or simultaneous expression was easily performed in each serotype System. Specifically, it produced viral-like particles of a triple layer in which the rotavirus structural proteins VP2, VP6 and VP7 were simultaneously expressed. The virus-like particles were similar to natural infectious rotavirus, and were presented to immune cells in the body while maintaining the antigenic structure. Can induce an immune response, and has no virulence because it does not contain a virus gene necessary for virus multiplication.

본 발명에서 사용되는 용어, "형질전환"은 본래의 세포가 가지고 있던 것과 다른 종류의 외래 유전자가 있는 DNA사슬 조각 또는 플라스미드가 세포들 사이에 침투되어 원래 세포에 존재하던 DNA와 결합함으로써 세포의 유전형질을 변화시키는 분자생물학적 기술을 의미한다. 본 발명에서 형질전환은 상기 로타바이러스 구조 단백질 유전자가 효모 세포 내로 삽입되는 것을 의미한다. 일반적으로 형질전환에는 유전자를 발현할 수 있는 플라스미드 DNA가 세포 안으로 들어가는 형태, 그리고 선형의 플라스미드 DNA가 들어가서 일련의 분자생물학적 반응을 통해 숙주세포의 Genome 안으로 삽입되어 integration되는 형태가 있다. 본 발명에서는, 딸세포로 분화할 때에 플라스미드 DNA 형태로 남아 있는 것보다 Genome 안으로 삽입되어 있는 것이 더욱 안정적이라는 점으로 고려하여, 피키아 파스토리스의 Genome에 로타바이러스 구조 단백질 유전자를 integration 시키는 방법을 사용하였다.As used herein, the term "transformation" refers to a process in which a DNA strand or plasmid having a heterologous gene of a different kind from that of the original cell is transfected into cells and binds to DNA originally present in the cell, It is a molecular biologic technique that changes traits. The transformation in the present invention means that the rotavirus structural protein gene is inserted into yeast cells. In general, transformation involves the insertion of a plasmid DNA capable of expressing a gene into a cell, and the insertion of a linear plasmid DNA into a genome of a host cell through a series of molecular biological reactions. In the present invention, a method of integrating the rotavirus structural protein gene into the genome of Pichia pastoris was used in consideration of the fact that it is more stable to insert into the genome than to remain in the form of plasmid DNA when differentiated into daughter cells .

본 발명에서, 상기 형질전환은 바람직하게 서열번호 1로 표시되는 pPIC6-CAU200 VP2 벡터, 서열번호 2로 표시되는 pPICZ-CAU200 VP6 벡터, 및 서열번호 3으로 표시되는 pPIC3.5K-CAU200 VP7 벡터를 효모세포에 도입함으로써 수행될 수 있다. 본 발명의 효모 세포 내로 삽입되는 로타바이러스 구조 단백질 유전자는 효모 세포내에서의 발현을 최적화시키기 위하여 코돈을 분석한 후, 이에 맞추어 서열을 변경함으로써 제작하였다. 상기 VP2, VP6, 및 VP7 유전자는 바람직하게 각각 서열번호 4 내지 6일 수 있으며, 상기 염기서열의 상동체가 본 발명의 범위 내에 포함된다. 구체적으로 상기 유전자는 서열번호 1 내지 6의 염기서열과 각각 70% 이상, 바람직하게는 80% 이상, 더욱 바람직하게는 90% 이상, 가장 바람직하게는 95% 이상의 서열 상동성을 가지는 염기서열을 포함할 수 있다. In the present invention, the transformation is preferably carried out using the pPIC6-CAU200 VP2 vector represented by SEQ ID NO: 1, the pPICZ-CAU200 VP6 vector represented by SEQ ID NO: 2, and the pPIC3.5K-CAU200 VP7 vector represented by SEQ ID NO: 3, Into a cell. The rotavirus structural protein gene inserted into the yeast cells of the present invention was prepared by analyzing codons to optimize the expression in yeast cells and then changing the sequence accordingly. The VP2, VP6, and VP7 genes may preferably be SEQ ID NOS: 4 to 6, respectively, and homologues of the nucleotide sequences are included within the scope of the present invention. Specifically, the gene includes a nucleotide sequence having a sequence homology of 70% or more, preferably 80% or more, more preferably 90% or more, and most preferably 95% or more, with the nucleotide sequence of SEQ ID NO: 1 to 6 can do.

또한, 본 발명에서, 상기 효모 세포는 바람직하게 피키아 파스토리스(Pichia pastoris)일 수 있다. Further, in the present invention, the yeast cell may be preferably Pichia pastoris .

단계 b)에서는, 단계 a)에서 형질전환된 효모 세포를 메탄올이 첨가된 배지에서 배양한다. 이때, 로타바이러스 구조 단백질의 발현 증대를 위하여 메탄올을 첨가하고, 특정 시간 동안 배양시킨다는 점에 기술적 특징이 있다. 구체적으로, 메탄올의 농도는 0.5 내지 1.5% 농도이며, 배양시간은 24 내지 96시간일 수 있으며, 바람직하게는 메탄올의 농도가 1 내지 1.5%인 경우, 24 내지 48시간 배양하는 것일 수 있으나, 이에 제한되는 것은 아니다. In step b), the transformed yeast cells in step a) are cultured in a medium supplemented with methanol. At this time, methanol is added to increase expression of rotavirus structural protein, and the culture is performed for a specific time. Specifically, the concentration of methanol may be 0.5 to 1.5%, the incubation time may be 24 to 96 hours, preferably, when the concentration of methanol is 1 to 1.5%, it may be cultured for 24 to 48 hours, But is not limited to.

단계 c)에서는, 단계 b)에서 배양된 효모 세포를 용해시켜 세포 용해물을 얻는다. 이때, 바이러스 유사입자의 정제 수율의 증진을 위하여 특정한 세포파쇄 완충액을 사용할 수 있다. 구체적으로, 세포파쇄 완충액 A (Tris-HCl pH7.5, NaCl, CaCl2,EDTA(에틸렌다이아민테트라아세트산, ethylenediaminetetraacetic acid), PMSF(페닐메탄설포닐 플로라이드, phenylmethanesulfonyl fluoride), glycerol, Tween20)일 수 있으나, 이에 제한되는 것은 아니다. In step c), the yeast cells cultured in step b) are lysed to obtain a cell lysate. At this time, a specific cell disruption buffer may be used for improving the yield of purification of virus-like particles. Specifically, a cell-destroying buffer A (Tris-HCl pH 7.5, NaCl, CaCl 2 , EDTA (ethylenediaminetetraacetic acid), PMSF (phenylmethanesulfonyl fluoride), glycerol, Tween 20) But is not limited thereto.

단계 d)에서는, 단계 c)에서의 세포 용해물로부터 로타바의 바이러스 유사입자를 분리 및 정제한다. 상기 분리 및 정제는 바람직하게는 원심 분리법을 통해 실시할 수 있으나, 바이러스 유사입자를 분리 정제할 수 있는 당업계에서 널리 알려진 방법을 통해서도 제한없이 실시할 수 있다.In step d), virus-like particles of rotava are separated and purified from the cell lysate in step c). The separation and purification can be carried out preferably by centrifugation, but may be carried out without limitation by methods well known in the art capable of separating and purifying virus-like particles.

본 발명의 일 실시예에서, pPIC6-CAU200 VP2 벡터, pPICZ-CAU200 VP6 벡터, 및 pPIC3.5K-CAU200 VP7 벡터를 피키아 파스토리스 GS115(HIS4)에 도입하여 형질전환시키고, 로타바이러스 구조 단백질(VP2, VP6, VP7)의 발현을 확인하였으며, 이로부터 바이러스 유사입자를 분리 정제 하였다(실시예 2 내지 4 참조). 또한, 본 발명의 다른 실시예서는, 상기 로타바이러스의 바이러스 유사입자를 처리한 군에서, 바이러스 유사 입자의 우수한 면역원성을 확인하였으며, 메탄올 농도 및 발현 유도시간을 최적화하여 로타바이러스 구조 단백질들의 발현양을 증대시켰을 뿐만 아니라, 재조합 단백질들의 용해도를 높일 수 있는 세포파쇄 완충액(Cell lysis buffer)으로 세포파쇄 완충액 A (Tris-HCl pH7.5, NaCl, CaCl2, EDTA, PMSF, glycerol, Tween20)를 이용하여 바이러스 유사입자의 정제 효율을 높일 수 있음을 확인하였다(실시예 5 내지 7 참조).In one embodiment of the present invention, pPIC6-CAU200 VP2 vector, pPICZ-CAU200 VP6 vector, and pPIC3.5K-CAU200 VP7 vector were transformed by introduction into Pichia pastoris GS115 (HIS4) and transformed with the rotavirus structural protein VP2 , VP6, and VP7), and the virus-like particles were isolated and purified (see Examples 2 to 4). In another embodiment of the present invention, excellent immunogenicity of virus-like particles was confirmed in the group treated with virus-like particles of the rotavirus, and the expression level of rotavirus structural proteins was optimized by optimizing methanol concentration and induction time (Tris-HCl pH 7.5, NaCl, CaCl 2 , EDTA, PMSF, glycerol, Tween 20) was used as a cell lysis buffer to increase the solubility of recombinant proteins It was confirmed that the purification efficiency of the virus-like particles can be increased (see Examples 5 to 7).

이에, 본 발명은 로타바이러스(Rotavirus)의 바이러스 유사입자(virus-like particle)를 포함하는, 면역원성 조성물을 제공한다.Accordingly, the present invention provides an immunogenic composition comprising a virus-like particle of Rotavirus.

본 발명에서 사용되는 용어, "면역원성"은 특정 병원체에 대해 면역 반응을 유발시키는 조성물의 능력을 의미한다. 면역 반응은 세포독성 T-세포 및 사이토카인-생성 T-세포에 의해 주로 매개되는 세포 면역 반응, 또는 헬퍼 T-세포에 의해 주로 매개된 후 B-세포를 활성화시켜 항체를 생성시키는 체액 면역 반응일 수 있다.As used herein, the term "immunogenicity" refers to the ability of a composition to elicit an immune response against a particular pathogen. The immune response is a cellular immune response that is primarily mediated by cytotoxic T-cells and cytokine-producing T-cells, or a humoral immune response that produces antibodies by activating B-cells after being mediated primarily by helper T- .

본 발명의 면역원성 조성물은, 로타바이러스의 바이러스 유사입자에 더하여, 약제학적으로 허용되는 담체 또는 아주반트를 추가로 포함할 수 있다. 상기 담체는 희석제, 완충제, 보존제 등을 포함하는 의미로서 사용된다. 상기 담체에는 당업계에 알려진 부형제, 붕해제, 결합제 및 활택제로 이루어진 군으로부터 선택된 1 이상의 성분이 포함될 수 있으나, 이에 제한되는 것은 아니다. 또한, 상기 아주반트는 항원의 면역원성을 증진시키기 위하여 사용되는 물질이며, 본 발명에 사용하기에 적합한 아주반트로서, 미네랄 염, 예컨대 Alum, 알루미늄 히드록시드, 알루미늄 포스페이트 및 칼슘 포스페이트; 계면활성제 및 미립자, 예컨대, 비이온성 블록 중합체 계면활성제(콜레스테롤), 비로솜(virosome), 사포닌(saponin)(Quil A, QS-21 및 GPI-0100), 프로테오솜, 면역 자극 착체, 코클레에이트, 4차 아민(디메틸 디옥타데실 암모늄 브로마이드(DDA)), 아브리딘, 비타민 A, 비타민 E; 박테리아 생성물, 예컨대 RIBI 아주반트 시스템(Ribi Inc.), 미코박테리룸 플레이(Mycobacterum phlei)의 세포벽 골격(Detox(등록상표)), 무라밀 디펩티드(MDP) 및 트리펩티드(MTP), 모노포스포릴 지질 A, 바실러스 칼메테-구에린(Bacillus Calmete-Guerin), 열-불안정한 대장균 엔테로톡신(enterotoxin), 콜레라 독소, 트레할로스 디미콜레이트, CpG 올리고데옥시뉴클레오티드; 사이토카인 및 호르몬, 예컨대, 인터류킨(IL-1, IL-2, IL-6, IL-12, IL-15, IL-18), 과립구집락자극인자, 데히드로에피안드로스테론, 1,25-디히드록시 비타민 D3; 폴리아니온, 예컨대 덱스트란; 폴리아크릴릭(예컨대, 폴리메틸메타크릴레이트, Carbopol 934P); 담체, 예컨대 테타누스 톡시드, 딥테리아 톡시드, 콜레라 독소 B 서브유닛, 엔테로톡시제닉 대장균의 돌연변이체 열-불안정한 엔테로톡신(rmLT), 열 쇼크 단백질; 수중유적형 유화액, 예컨대 AMPHIGEN(등록상표)(Hydronics, 미국); 및 유중수적형 유화액, 예컨대 프로인트(Freund)의 완전 및 불완전 아주반트가 포함되지만, 이에 제한되는 것은 아니다.The immunogenic compositions of the present invention may further comprise a pharmaceutically acceptable carrier or adjuvant, in addition to virus-like particles of rotavirus. The carrier is used as a meaning including a diluent, a buffer, a preservative and the like. The carrier may include, but is not limited to, one or more components selected from the group consisting of excipients, disintegrants, binders and glidants known in the art. The adjuvant is a substance used for enhancing the immunogenicity of an antigen and is an adjuvant suitable for use in the present invention, and includes mineral salts such as Alum, aluminum hydroxide, aluminum phosphate and calcium phosphate; Surfactants and particulates such as nonionic block polymer surfactants (cholesterol), virosomes, saponins (Quil A, QS-21 and GPI-0100), proteosomes, immunostimulatory complexes, (Dimethyldioctadecylammonium bromide (DDA)), avidin, vitamin A, vitamin E; Bacterial products such as the RIBI Ribi Inc. cell wall skeleton of Mycobacterum phlei (Detox TM), muramyldipeptide (MDP) and tripeptide (MTP), monophosphate Bacillus Calmete-Guerin, heat-labile Escherichia coli enterotoxin, cholera toxin, trehalose dimicolate, CpG oligodeoxynucleotides; IL-12, IL-15, IL-18), granulocyte colony stimulating factor, dehydroepiandrosterone, 1,25-di Hydroxyvitamin D3; Polyanions such as dextran; Polyacrylic (e.g., polymethyl methacrylate, Carbopol 934P); Carriers such as tetanus toxide, dipteryatocide, cholera toxin B subunit, mutant heat-labile enterotoxin (rmLT) of enterotoxigenic E. coli, heat shock protein; Water-in-oil emulsions such as AMPHIGEN (R) (Hydronics, USA); And water-in-oil emulsions such as, for example, Freund's complete and incomplete adjuvants.

본 발명의 면역원성 조성물은 당업계에 알려진 임의의 형태 예를 들면, 액제 및 주사제의 형태일 수 있으나, 이에 제한되는 것은 아니다. 액제 또는 주사제의 경우, 필요시 10∼40%의 프로필렌 글리콜, 및 용혈현상을 방지하는데 충분한 양 (예: 약 1%)의 염화나트륨을 함유할 수 있다. 상기 액제 또는 주사제에는 당업계에 알려진 임의의 희석제 또는 완충제가 포함될 수 있다. 또한, 본 발명의 면역원성 조성물은, 로타바이러스 유사입자를 바이알과 같은 용기에 보존하고, 사용하기 전에 주사제에 필요한 담체 또는 아주반트, 식염수 등을 부가함으로써 사용 직전에 조제될 수도 있다.The immunogenic compositions of the present invention may be in any form known to those skilled in the art, for example, in the form of solutions and injections, but are not limited thereto. For liquids or injections, it may contain 10 to 40% of propylene glycol if necessary, and sodium chloride in an amount sufficient to prevent hemolysis (e.g., about 1%). The liquid or injectable solution may contain any diluents or buffers known in the art. The immunogenic compositions of the present invention may also be prepared immediately prior to use by preserving the rotavirus-like particles in a container such as a vial and adding a carrier or adjuvant, saline solution or the like necessary for the injection before use.

본 발명의 면역원성 조성물은, 당업계에 알려져 있는 임의의 투여 수단에 의하여 투여될 수 있다. 예를 들면, 상기 투여는 정맥내, 근육내, 경구, 경피 (transdermal), 점막, 코안 (intranasal), 기관내 (intratracheal) 또는 피하로 개체로 직접적으로 투여될 수 있다. 상기 투여는 전신적으로 또는 국부적으로 투여되는 것일 수 있다.The immunogenic compositions of the invention may be administered by any means of administration known in the art. For example, the administration can be administered directly into an individual by intravenous, intramuscular, oral, transdermal, mucosal, intranasal, intratracheal or subcutaneous administration. The administration may be systemically or locally administered.

본 발명의 면역원성 조성물은, 치료학적으로 또는 예방학적으로 유효한 양으로 투여될 수 있다. 상기 "치료학적으로 또는 예방학적으로 유효한 양"은 치료 또는 예방하고자 하는 증상을 완화 또는 제거하는데 요구되는 양을 의미하며, 증상의 경중, 개체의 성별, 나이 및 체중 등을 고려하여 적절하게 선택할 수 있다.The immunogenic compositions of the invention may be administered in a therapeutically or prophylactically effective amount. The "therapeutically or prophylactically effective amount" means an amount required for relieving or eliminating symptoms to be treated or prevented, and may be appropriately selected in consideration of the severity of symptoms, sex, have.

본 발명의 다른 양태로서, 본 발명은 상기 면역원성 조성물을 개체에 투여하는 단계를 포함하는 로타바이러스 감염증의 예방 또는 치료방법을 제공한다. 본 발명에서 "개체"란 질병의 치료를 필요로 하는 대상을 의미하고, 보다 구체적으로는, 인간 또는 비-인간인 영장류, 생쥐(mouse), 개, 고양이, 말, 및 소 등의 포유류를 의미한다.In another aspect of the present invention, the present invention provides a method of preventing or treating rotavirus infection comprising administering the immunogenic composition to a subject. The term " individual "as used herein refers to a subject in need of treatment of a disease, and more specifically refers to a mammal such as a human or non-human primate, mouse, dog, cat, horse, do.

이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예를 제시한다. 그러나 하기의 실시예는 본 발명을 보다 쉽게 이해하기 위하여 제공되는 것일 뿐, 하기 실시예에 의해 본 발명의 내용이 한정되는 것은 아니다.Hereinafter, preferred embodiments of the present invention will be described in order to facilitate understanding of the present invention. However, the following examples are provided only for the purpose of easier understanding of the present invention, and the present invention is not limited by the following examples.

[실시예][Example]

실시예 1. 실험 준비Example 1. Experimental preparation

1-1. 로타바이러스 구조 단백질 유전자의 분리 및 코돈 최적화1-1. Isolation and codon optimization of rotavirus structural protein gene

로타바이러스 감염 환자로부터 한국 인간 로타바이러스 CAU200 균주 (GenBank 첨부 번호 : KT207485, ACD50880, ACD50874)를 분리하였다. 이후, 발현 균주인 피키아 파스토리스(Pichia pastoris)의 발현 시스템에 적합하도록 인간 로타바이러스 구조 단백질(VP2, VP6, VP7)을 코딩하는 유전자를 GeneArt (Regensberg, Germany)에서 코돈 최적화(codon optimization)하였다.Korean human rotavirus CAU200 strain (GenBank Attachment No .: KT207485, ACD50880, ACD50874) was isolated from patients with rotavirus infection. Subsequently, a gene encoding human rotavirus structural proteins (VP2, VP6, VP7) was codon optimized in GeneArt (Regensberg, Germany) to fit the expression system of the expression strain Pichia pastoris .

1-2. 효모 균주 및 재조합 플라스미드 벡터의 준비1-2. Preparation of yeast strains and recombinant plasmid vectors

로타바이러스 구조 단백질의 발현 균주로서, 피키아 파스토리스 GS115(HIS4)를 이용하였다. 또한, 피키아 파스토리스에 로타바이러스 구조 단백질인 VP2, VP6, 또는 VP7을 도입하기 위하여, 상기 구조 단백질 유전자들을 각각 pPIC6, pPICZ, 또는 pPIC3.5K (Invitrogen, Carlsbad, CA, USA) 플라스미드 벡터에 서브클로닝(subcloning)하였다. 상기 pPIC6 및 pPICZ 플라스미드 벡터는 피키아 파스토리스와 대장균 모두에서 기능을 갖는 선택적 마커로 각각 Blastcidin (Invitrogen)과 Zeocin (Invitrogen)을 포함하며, 상기 pPIC3.5K 벡터는 피키아 파스토리스에서는 Geneticin (Invitrogen), 대장균에서는 kanamycin 내성을 갖도록 설계하였다. 아울러, 플라스미드 벡터에 삽입된 유전자는 DNA 염기서열 분석을 통하여 확인하였다.As a strain expressing the rotavirus structural protein, Pichia pastoris GS115 (HIS4) was used. Also, in order to introduce VP2, VP6 or VP7, which is a rotavirus structural protein, into Pichia pastoris, the above structural protein genes are respectively added to pPIC6, pPICZ, or pPIC3.5K (Invitrogen, Carlsbad, CA, USA) Followed by subcloning. The pPIC6 and pPICZ plasmid vectors include Blastcidin (Invitrogen) and Zeocin (Invitrogen) as selective markers having functions in both Pichia palliatis and Escherichia coli, and the pPIC3.5K vector is Geneticin (Invitrogen) in Pichia pastoris. , And E. coli was designed to have kanamycin resistance. In addition, the gene inserted into the plasmid vector was confirmed by DNA sequencing.

실시예 2. 재조합 플라스미드 벡터를 이용한 형질전환 및 확인Example 2. Transformation and confirmation using a recombinant plasmid vector

본 실시예에서는 상기 실시예 1에서 준비한 재조합 플라스미드 벡터를 피키아 파스토리스 GS115(HIS4)에 도입하여 형질전환시키고자 하였으며, 상기 형질전환 과정은 도 1에 개략적으로 나타내었다. 구체적으로, pPIC6-CAU200 VP2 플라스미드는 SacI (New England BioLab) 제한효소를 처리하여 선형으로 제조하였으며, 제조사 지침에 따라 Pichia EasyComp Kit (Invitrogen)을 사용하여 피키아 파스토리스 GS115 균주에 형질전환을 시켰다. 형질전환된 효모세포는 300mg/ml의 Blasticidin을 포함한 YPDS 한천배지를 이용하여 30℃ 조건 하에서 3-4일 동안 배양하였으며, Blasticidin 내성 콜로니들 중에서 유전자가 삽입된 형질전환체를 콜로니 중합효소 연쇄반응 (Polymerase chian reaction, PCR)을 통하여 확인하였다. 두 번째 형질 전환은, VP2가 도입된 피키아 파스토리스 GS115-cauVP2에 CAU 200 VP6(pPICZ-CAU200 VP6)를 삽입하여 형질전환체를 제조하였으며, 세 번째 형질 전환은, VP2 및 VP6가 도입된 피키아 파스토리 GS115-cau26 (VP2/VP6)에 CAU200 VP7(pPIC3.5K-CAU200 VP7)을 삽입하여 형질전환체를 제조하였다. 상기 방법을 통하여 최종적으로 3개의 로타바이러스 구조 단백질(VP2, VP6, VP7) 유전자가 삽입된 GS115-cau267을 생산하였다. In this Example, the recombinant plasmid vector prepared in Example 1 was introduced into Pichia pastoris GS115 (HIS4) and transformed. The transformation process is schematically shown in FIG. Specifically, the pPIC6-CAU200 VP2 plasmid was linearized by treating with SacI (New England BioLab) restriction enzyme and transformed into Pichia pastoris GS115 strain using the Pichia EasyComp Kit (Invitrogen) according to the manufacturer's instructions. Transformed yeast cells were cultured for 3 to 4 days at 30 ° C in a YPDS agar medium containing 300 mg / ml of Blasticidin. The transformants inserted in the blasticidin-resistant colonies were subjected to colony polymerase chain reaction Polymerase chain reaction (PCR). In the second transformation, a transformant was prepared by inserting CAU 200 VP6 (pPICZ-CAU200 VP6) into Pichia pastoris GS115-cauVP2 into which VP2 was introduced, and the third transformation was carried out by adding VP2 and VP6 A transformant was prepared by inserting CAU200 VP7 (pPIC3.5K-CAU200 VP7) into the Kiapas strain GS115-cau26 (VP2 / VP6). Finally, GS115-cau267 with three rotavirus structural proteins (VP2, VP6, VP7) inserted therein was produced.

또한, 상기 형질전환된 피키아 파스토리스 콜로니에서 로타바이러스 구조 단백질(VP2, VP6, VP7)의 발현을 확인하기 위하여 콜로니 PCR을 실시한 후, 1.2% 아가로즈겔에서 전기영동하였으며, 대조군으로는 AOX1 프라이머를 이용하였으며, 본 실시예에서 사용한 프라이머 염기서열은 하기 표 1에 나타내었다. In order to confirm the expression of rotavirus structural proteins (VP2, VP6, VP7) in the transformed Pichia pastoris colonies, colony PCR was performed and electrophoresis was performed on 1.2% agarose gel. As a control group, AOX1 primer The primer sequences used in this Example are shown in Table 1 below.

Figure 112015093709020-pat00001
Figure 112015093709020-pat00001

그 결과 도 2에 나타낸 바와 같이, 형질전환된 피키아 파스토리스 콜로니에서, 2208bp의 VP2, 773bp의 VP6, 및 782bp의 VP7 구조 단백질을 확인하였으며, 이는, 상기 재조합 플라스미드(pPIC6-CAU200 VP2, pPICZ-CAU200 VP6, pPIC3.5K-CAU200 VP7)를 통해 로타바이러스 구조 단백질(VP2, VP6, VP7)이 발현 균주인 피키아 파스토리스 GS115(HIS4)에 도입되어 형질전환되었음을 나타낸다. As a result, as shown in Fig. 2, in the transformed Pichia pastoris colonies, VP2 of 2208 bp, VP6 of 773 bp, and VP7 structural protein of 782 bp were confirmed, and the recombinant plasmids (pPIC6-CAU200 VP2, pPICZ- (VP2, VP6, VP7) was introduced into an expression strain, Pichia pastoris GS115 (HIS4), through the expression plasmid pCIC200, CAU200 VP6 and pPIC3.5K-CAU200 VP7.

실시예 3. 로타바이러스 구조 단백질의 발현 유도 및 확인Example 3 Induction and Identification of Rotavirus Structural Protein

상기 실시예 2에서 제조한 양성 형질전환체인 GS115-cau267을 20mL YPD 액체 배지(1% w/v yeast extract, 2 % w/v peptone and 2 % w/v dextrose)에 접종하여 30℃, 180rpm 조건하에서 하루 동안 진탕배양(shake culture)하였다. 배양된 세포는 5,000rpm, 5분, 4℃ 조건 하에서 원심분리하여 얻었으며, 얻은 세포를 300mL MGY 액체 배지(1.34% w/v yeast nitrogen base, 0.05% w/v biotin and 1% v/v glycerol)에 부유시킨 뒤, 30℃, 180rpm 조건하 OD 600nm에서 2.0-6.0 도달할 때까지 진탕배양하였다. 배양된 세포는 원심분리하여 얻었으며, 얻은 세포를 500mL의 MM 액체 배지(1.34% w/v yeast nitrogen base, 0.05% w/v biotin and 0.5-1.5% v/v methanol)에 부유시켜 OD 600nm의 1.0에 도달할 때까지 30℃에서 180rpm으로 24-96시간 동안 진탕배양하여 VP2, VP6, 및 VP7 단백질들을 발현시켰다. 배양된 세포는 4℃ 조건하에서 5,000rpm, 5분 동안 원심분리하여 상층액과 세포 펠렛을 얻었다. 수득한 세포 펠렛을 세포파쇄 완충액 A(10mM Tris-HCl pH 7.5, 140mM NaCl, 10mM CaCl2, 1mM EDTA, 1mM PMSF, 5% v/v glycerol, 0.01% v/v Tween20)에 녹이고 유리 비드(Sigma, USA)와 함께 비드-비터(Bead-Beater)(Biospec Products, USA)의 챔버로 옮긴 후, 5분간 흔들어 세포를 파쇄하였다. 용해물(lysate)을 4℃에서 12,000 x g의 속도로 30분 동안 원심분리하여 맑은 상층액을 얻었다.The positive transformant GS115-cau267 prepared in Example 2 was inoculated in 20 mL of YPD liquid medium (1% w / v yeast extract, 2% w / v peptone and 2% w / v dextrose) Under shaking culture for one day. The cultured cells were obtained by centrifugation at 5,000 rpm for 5 minutes at 4 ° C. The obtained cells were suspended in 300 mL of MGY liquid medium (1.34% w / v yeast nitrogen base, 0.05% w / v biotin and 1% v / v glycerol ), And then cultured with shaking at 30 ° C and 180 rpm at OD 600nm until reaching 2.0-6.0. The cultured cells were obtained by centrifugation and the obtained cells were suspended in 500 mL of MM liquid medium (1.34% w / v yeast nitrogen base, 0.05% w / v biotin and 0.5-1.5% v / v methanol) VP2, and VP7 proteins were expressed by shaking culturing at 30 DEG C and 180 rpm for 24-96 hours until 1.0. The cultured cells were centrifuged at 5,000 rpm for 5 minutes at 4 ° C to obtain supernatants and cell pellets. The obtained cell pellet was dissolved in cell disruption buffer A (10 mM Tris-HCl pH 7.5, 140 mM NaCl, 10 mM CaCl 2 , 1 mM EDTA, 1 mM PMSF, 5% v / v glycerol, 0.01% v / v Tween 20) , USA) in a bead-beater (Biospec Products, USA) and shaken for 5 minutes to disrupt the cells. The lysate was centrifuged at 4,000 rpm at a rate of 12,000 xg for 30 minutes to obtain a clear supernatant.

또한, 상기 수득한 상층액에 존재하는 바이러스 유사입자 내 로타바이러스 구조 단백질(VP2, VP6, VP7)의 발현을 확인하기 위하여 상기 상층액 내 단백질을 10% SDS-PAGE 상에서 전기영동하였으며, 모든 단백질 성분은 Immuno-BlotTM PVDF membrane (Bio-Rad)에 옮긴 후, 이 멤브레인(memebrane)을 5% 탈지유를 이용하여 블로킹(blocking)하였다. 쥐로부터 수득한 단일클론 항-His 항체(antibody) 및 토끼로부터 수득한 다클론 로타바이러스 Wa 항혈청을 1차 항체로 이용하였으며, 5% 탈지유 용액 내 보관하였다. 상기 1차 항체를 사용하여 1시간 동안 반응시키고, peroxidase-conjugated goat anti-rabbit IgG (1:2000 dilution, Invitrogen)를 2차 항체로 사용하여 다시 반응시켰다. 발현된 단백질은 ECL(electrochemiluminescence) 기법을 이용하여 ImageQuant LAS4000 (GE Healthcare, USA)에서 확인하였다. In order to confirm the expression of rotavirus structural proteins (VP2, VP6, VP7) in viral-like particles present in the obtained supernatant, the protein in the supernatant was electrophoresed on 10% SDS-PAGE, Was transferred to an Immuno-BlotTM PVDF membrane (Bio-Rad), and the membrane was blocked with 5% skim milk. Monoclonal anti-His antibodies obtained from rats and polyclonal rotavirus Wa antiserum obtained from rabbits were used as primary antibodies and stored in 5% skim milk solution. The reaction was carried out for 1 hour using the primary antibody and reacted again with peroxidase-conjugated goat anti-rabbit IgG (1: 2000 dilution, Invitrogen) as a secondary antibody. Expressed proteins were identified by ImageQuant LAS4000 (GE Healthcare, USA) using ECL (electrochemiluminescence) technique.

그 결과, 도 3에 나타낸 바와 같이, 쥐의 단일클론 항-His 항체(도 3a) 및 토끼의 다클론 로타바이러스 Wa 항혈청(도 3b) 실험에서 로타바이러스 구조 단백질인 VP2, VP6, 및 VP7의 발현을 확인하였다.As a result, as shown in Fig. 3, expression of rotavirus structural proteins VP2, VP6, and VP7 in rat monoclonal anti-His antibody (Fig. 3A) and rabbit polyclonal rotavirus Wa antiserum Respectively.

실시예 4. 바이러스 유사 입자의 순수 분리 및 정제 Example 4. Pure isolation and purification of virus-like particles

상기 실시예 3에서의 세포 용해물을 12,000rpm에서 30분 동안 초고속 원심분리하여 맑은 상층액을 얻었다. 바이러스 유사입자를 함유하고 있는 상층액에 35% 수크로오스 쿠션(sucrose in TNC buffer, 10mM Tris-HCl, pH 7.5, 140mM NaCl, 10mM CaCl2)을 첨가하고, SW32Ti 로터(Beckman Coulter)를 이용하여 30,000rpm에서 120분 동안 원심분리함으로써 바이러스 유사입자 침전물을 얻었다. 수득한 바이러스 유사입자 침전물은 4㎖의 TNC 완충액에 부유시켰고, CsCl이 0.42g/ml 농도로 녹아있는 TNC 완충액을 첨가하고 SW41Ti 로터(Beckman Coulter)를 이용하여 35,000rpm에서 18시간 동안 원심분리하였다. 원심분리한 후, 확인된 2개의 밴드, 즉 하위 밴드와 상위밴드를 일회용 주사기를 이용하여 회수하였고, CsCl의 제거를 위해 TNC 완충액으로 투석(dialysis)하였다.The cell lysate of Example 3 was subjected to ultrafast centrifugation at 12,000 rpm for 30 minutes to obtain a clear supernatant. 35% sucrose in TNC buffer (10 mM Tris-HCl, pH 7.5, 140 mM NaCl, 10 mM CaCl 2 ) was added to the supernatant containing virus-like particles and the mixture was centrifuged at 30,000 rpm using a SW32Ti rotor (Beckman Coulter) For 120 minutes to obtain a virus-like particle precipitate. The resulting virus-like particle precipitate was suspended in 4 ml of TNC buffer, and TNC buffer containing CsCl dissolved at a concentration of 0.42 g / ml was added and centrifuged at 35,000 rpm for 18 hours using a SW41 Ti rotor (Beckman Coulter). After centrifugation, the two identified bands, the lower and upper bands, were recovered using a disposable syringe and dialysed with TNC buffer to remove CsCl.

또한, 상기 수득한 바이러스 유사 입자의 존재를 확인하기 위하여 투과전자현미경 분석을 실시하였다. 구체적으로, Formvar-carbon이 코팅된 200 mesh copper 그리드(grid) 표면에 정제된 로타바이러스 바이러스 유사입자 샘플을 올려 놓은 후, 30초 뒤에 그리드로부터 용액 대부분을 필터 페이퍼로 제거하였다. 상기 그리드 위에 uranyl acetate 용액을 올려 30초간 염색한 후, 건조시켰으며, 샘플은 NICEM(The National Instrumentation Center of Environmental Management, Seoul National University) 안에 있는 JEM1010 모델(JEOL, Japan)을 사용하여 관찰하였다. Transmission electron microscopy analysis was performed to confirm the presence of the virus-like particles. Specifically, a purified rotavirus virus-like particle sample was placed on the surface of a 200 mesh copper grid coated with Formvar-carbon, and 30 seconds later, most of the solution was removed from the grid with filter paper. The uranyl acetate solution was placed on the grid and dyed for 30 seconds and dried. The samples were observed using a JEM1010 model (JEOL, Japan) in NICEM (National Instrumentation Center of Environmental Management, Seoul National University).

그 결과, 도 4에 나타낸 바와 같이, 투과전자현미경을 통해 1% uranyl acetate로 염색된 바이러스 유사 입자를 확인할 수 있었다. As a result, as shown in FIG. 4, virus-like particles stained with 1% uranyl acetate were confirmed through a transmission electron microscope.

실시예 5. 바이러스 유사 입자의 면역성 확인 Example 5. Identification of the immunity of virus-like particles

본 실시예에서는, 동물 모델을 이용하여 상기 방법에 의해 제조된 로타바이러스의 바이러스 유사 입자의 면역원성을 확인하고자 하였다. 50㎍의 정제된 로타바이러스 바이러스 유사입자를 7주령 Balb/c 암컷 쥐에 완전 프로인드 면역 반응항진제(complete Freund's adjuvant)와 함께 피하 주사한 후(Day 0), 28일에 다시 불완전 프로인드 면역반응항진제(incomplete Freund's adjuvant)와 함께 부스팅(boosting)하였다. 40일 후, 심장으로부터 혈액을 채취하고, 혈청을 분리한 후, 항체형성 여부를 ELISA 기법을 이용하여 확인하였으며, 대조군으로는 아무 주사도 하지 않은 음성 Balb/c 암컷 쥐 혈청의 항체와, 항원이 들어있지 않은 면역반응항진제(adjuvant)를 주사한 음성 Balb/c 암컷 쥐 혈청의 항체를 이용하였다. 구체적으로, 분리 정제한 로타바이러스 Wa 항원을 웰(well) 당 0.1μg 농도로 코팅 용액(0.1M Na2CO3, 0.1M NaHCO3, pH 9.4) 내에 준비한 후, 96-웰 면역플레이트(immunoplate)에 4℃에서 하루 동안 코팅하였다. 코팅된 플레이트를 PBS-T(1 X PBS with 0.05% Tween20) 200㎕로 3회 세척한 후, 5% (w/v) 탈지유를 사용하여 블로킹하였다. 쥐로부터 수득한 면역 혈청을 단계별로 희석하였으며, 이후, 37℃에서 1시간 동안 반응시켰다. 세척 후, peroxidase-conjugated goat anti-rabbit IgG (diluted in PBS-T, 5% 탈지유 함유)를 웰 당 100㎕씩 첨가한 후, 37℃에서 1시간 반응시켰다. 기질 용액으로서 OPD(ortho-phenylenediamine)를 첨가한 후, 5분 동안 반응시켰으며, 1M H2SO4 50㎕를 각 웰에 첨가하여 반응을 중지시켰다. 이후, ELISA reader(NanoQuant)를 이용하여 450nm에서 흡광도를 측정하여 항체 농도(항체가)를 정량하였다. In this Example, animal models were used to determine the immunogenicity of virus-like particles of rotavirus prepared by the above method. 50 [mu] g of purified rotaviral virus-like particles were subcutaneously injected (Day 0) into 7-week-old Balb / c female rats with complete Freund's adjuvant, followed by incomplete pro- And boosted with an incomplete Freund's adjuvant. After 40 days, blood was collected from the heart, serum was separated, and antibody formation was confirmed by ELISA. As a control group, the antibody of the negative Balb / c female rat serum and the antigen Antibodies of negative Balb / c female rat sera injected with an immune response adjuvant were used. Specifically, the separated and purified rotavirus Wa antigen was prepared in a coating solution (0.1 M Na 2 CO 3 , 0.1 M NaHCO 3 , pH 9.4) at a concentration of 0.1 μg per well, and then immersed in a 96-well immunoplate 0.0 > 4 C < / RTI > for one day. The coated plates were washed three times with 200 [mu] l PBS-T (1 x PBS with 0.05% Tween 20) and then blocked with 5% (w / v) skim milk. The immunized sera obtained from the rats was diluted step by step and then reacted at 37 DEG C for 1 hour. After washing, peroxidase-conjugated goat anti-rabbit IgG (diluted in PBS-T, containing 5% skim milk) was added in an amount of 100 μl per well, followed by reaction at 37 ° C for 1 hour. OPD (ortho-phenylenediamine) was added as a substrate solution, followed by reaction for 5 minutes, and 50 μl of 1M H 2 SO 4 was added to each well to stop the reaction. Thereafter, the absorbance was measured at 450 nm using an ELISA reader (NanoQuant) to quantify the antibody concentration (antibody value).

그 결과, 도 5에 나타낸 바와 같이, 대조군에 비교하여 로타바이러스의 바이러스 유사 입자를 처리한 군에서 유의적으로 높은 면역혈청의 항체가를 확인하였다. 이를 통해, 상기 방법에 의해 제조된 로타바이러스의 바이러스 유사 입자는 높은 면역원성을 나타내는 바, 면역원성 조성물로 활용할 수 있음을 알 수 있다. As a result, as shown in Fig. 5, antibody titer of significantly higher immunity sera was confirmed in the group treated with virus-like particles of rotavirus as compared with the control group. As a result, the virus-like particles of the rotavirus produced by the above method show high immunogenicity and thus can be utilized as an immunogenic composition.

실시예 6. 최적의 바이러스 유사 입자 생산을 위한 배양 조건 확인Example 6. Confirmation of culture conditions for production of optimal virus-like particles

본 실시예에서는, 피키아 파스토리스에서 재조합 단백질의 생산에 있어서, 메탄올 퍼센트 농도(v/v %)와 발현 유도시간(induction time)이 중요한 요소라는 점에 기반하여, 배양시 첨가되는 메탄올 농도 및 발현 유도시간에 따른 로타바이러스 구조 단백질 발현양 차이를 비교하였다. 구체적으로, 각각의 메탄올 함유량은 각 0.5, 0.75, 1.0, 1.5% (v/v)로 최종 농도를 결정하였으며, 매 24 시간마다 세포를 수득하여 4일 동안 측정하였다. 매 24시간마다 최종 농도를 유지하기 위하여 각기 농도에 맞추어 100% 메탄올을 첨가하였다. 세포파쇄 완충액 A를 이용하여 4℃ 조건하에서 5,000rpm, 5분 동안 원심분리하여 세포 잔여물을 제거하였다. 4℃ 조건에서 12,000xg로 10분간 원심분리를 한 뒤, 상층액을 얻어 사용 전까지 보관하였으며, 재조합 단백질 생산은 웨스턴 블로팅으로 확인하였다. 단백질의 생산의 수준의 정확한 양적 비교를 위해서, 조건마다 106 세포를 수득하여 샘플을 로딩하였으며, Image J 소프트웨어를 사용하여 Western blot 밴드의 농도를 비교를 하였다(Wayne Rasband, NIH, USA).Based on the fact that the concentration of methanol per cent (v / v%) and the induction time are important factors in the production of recombinant protein in Pichia pastoris in this example, The differences in the expression levels of rotavirus structural proteins with the induction time were compared. Specifically, the final concentration was determined for each methanol content of 0.5, 0.75, 1.0, 1.5% (v / v), and cells were obtained every 24 hours and measured for 4 days. 100% methanol was added to each concentration to maintain the final concentration every 24 hours. Cell debris was removed by centrifugation at 5,000 rpm for 5 minutes at 4 ° C using buffer A. After centrifugation at 12,000xg for 10 minutes at 4 ° C, supernatants were collected and stored until use, and recombinant protein production was confirmed by Western blotting. For a precise quantitative comparison of the level of protein production, 10 6 cells per condition were obtained to load the samples and the concentration of Western blot bands was compared using Image J software (Wayne Rasband, NIH, USA).

그 결과, 도 6에 나타낸 바와 같이, 0.5~0.75% 메탄올 첨가 조건에서 48~72시간 배양한 경우, 또는 1~1.5% 메탄올 첨가 조건에서 24~48시간 배양한 경우에 발현 유도된 재조합 단백질의 양이 증대됨을 확인하였다. 이를 통해, 메탄올 퍼센트 농도와 발현 유도시간을 조절함으로써, 로타바이러스 구조 단백질을 포함하는 재조합 단백질의 발현양을 증대시켜 파스토리스에서 로타바이러스의 바이러스 유사입자 생산을 극대화시킬 수 있음을 알 수 있다. As a result, as shown in Fig. 6, the amount of expression-induced recombinant protein when cultured for 48 to 72 hours under 0.5 to 0.75% methanol addition or for 24 to 48 hours under 1 to 1.5% methanol addition conditions Respectively. Thus, it can be seen that the production of viral-like particles of rotavirus can be maximized in Pasteuris by increasing the expression amount of a recombinant protein containing rotavirus structural protein by controlling the concentration of methanol percent and induction time of expression.

실시예 7. 세포 파쇄 완충액 차이에 따른 상층액 내 용해성 차이 확인Example 7. Confirmation of difference in solubility in supernatant depending on cell crush buffer difference

형질전환된 세포를 배양한 후, 이를 파쇄하여 수득한 상층액을 사용하여 정제단계로 진행되며, 이 과정에서 상층액에 보다 많은 재조합 단백질이 녹아 있는 경우, 생산 효율을 더욱 증대시킬 수 있다. 따라서 본 실시예에서는, 피키아 파스토리스에서 재조합 단백질의 생산에 있어서, 상층액 내 단백질 함량을 증진시키는 것이 중요한 요소라는 점에 기반하여, 세포 파쇄 완충액에 따른 상층액 단백질의 단백질 용해성(solubility)을 비교하였다. 구체적으로 일반적으로 사용하는 TNC 버퍼로 파쇄한 세포의 상층액 단백질과 세포파쇄 완충액 A로 파쇄한 세포의 상층액 단백질에서, 웨스턴 블로팅을 통해 각 재조합 단백질들의 발현 정도를 측정하였고, Image J 프로그램을 통해 정량하였다.After the transformed cells are cultured, the resulting supernatant is used for purification, and if more recombinant proteins are dissolved in the supernatant, the production efficiency can be further increased. Therefore, in this example, based on the fact that the increase of the protein content in the supernatant is an important factor in the production of recombinant protein in the Pichia pastoris, the solubility of the protein in the supernatant protein according to the cell- Respectively. Specifically, the degree of expression of each recombinant protein was measured by Western blotting on the supernatant protein of the cell lysed with the TNC buffer commonly used and the cell lysate protein disrupted with the cell disruption buffer A, Lt; / RTI >

그 결과, 도 7에 나타낸 바와 같이, 세포파쇄 완충액 A로 파쇄한 상층액에서 발현된 단백질의 양은 TNC 완충액으로 파쇄한 상층액과 비교하여 2배 이상 증가하였으며, 침전 단백질의 양은 42%에서 25%로 크게 감소함을 확인하였다. 이를 통해, 세포파쇄 완충액 A를 이용함으로써, 정제 효율을 높여 파스토리스에서 로타바이러스의 바이러스 유사입자 생산을 극대화시킬 수 있음을 알 수 있다. As a result, as shown in FIG. 7, the amount of protein expressed in the supernatant lysed with cell-disrupting buffer A was increased by more than 2 times as compared with the supernatant lysed with TNC buffer, and the amount of precipitated protein was increased from 42% to 25% As shown in Fig. Thus, it can be seen that, by using the cell disruption buffer A, the purification efficiency can be increased and the production of virus-like particles of rotavirus can be maximized in Pasteur.

전술한 본 발명의 설명은 예시를 위한 것이며, 본 발명이 속하는 기술분야의 통상의 지식을 가진 자는 본 발명의 기술적 사상이나 필수적인 특징을 변경하지 않고서 다른 구체적인 형태로 쉽게 변형이 가능하다는 것을 이해할 수 있을 것이다. 그러므로 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적이 아닌 것으로 이해해야만 한다.It will be understood by those skilled in the art that the foregoing description of the present invention is for illustrative purposes only and that those of ordinary skill in the art can readily understand that various changes and modifications may be made without departing from the spirit or essential characteristics of the present invention. will be. It is therefore to be understood that the above-described embodiments are illustrative in all aspects and not restrictive.

<110> Chung-Ang University Industry-Academy Cooperation Foundation <120> Method for Producing and Purifying Virus-Like Particle of Rotavirus using Yeast strain <130> CAU20151894KR_MP15-100 <160> 10 <170> KoPatentIn 3.0 <210> 1 <211> 6031 <212> DNA <213> Artificial Sequence <220> <223> pPIC6-CAU200 VP2 <400> 1 agatctaaca tccaaagacg aaaggttgaa tgaaaccttt ttgccatccg acatccacag 60 gtccattctc acacataagt gccaaacgca acaggagggg atacactagc agcagaccgt 120 tgcaaacgca ggacctccac tcctcttctc ctcaacaccc acttttgcca tcgaaaaacc 180 agcccagtta ttgggcttga ttggagctcg ctcattccaa ttccttctat taggctacta 240 acaccatgac tttattagcc tgtctatcct ggcccccctg gcgaggttca tgtttgttta 300 tttccgaatg caacaagctc cgcattacac ccgaacatca ctccagatga gggctttctg 360 agtgtggggt caaatagttt catgttcccc aaatggccca aaactgacag tttaaacgct 420 gtcttggaac ctaatatgac aaaagcgtga tctcatccaa gatgaactaa gtttggttcg 480 ttgaaatgct aacggccagt tggtcaaaaa gaaacttcca aaagtcggca taccgtttgt 540 cttgtttggt attgattgac gaatgctcaa aaataatctc attaatgctt agcgcagtct 600 ctctatcgct tctgaacccc ggtgcacctg tgccgaaacg caaatgggga aacacccgct 660 ttttggatga ttatgcattg tctccacatt gtatgcttcc aagattctgg tgggaatact 720 gctgatagcc taacgttcat gatcaaaatt taactgttct aacccctact tgacagcaat 780 atataaacag aaggaagctg ccctgtctta aacctttttt tttatcatca ttattagctt 840 actttcataa ttgcgactgg ttccaattga caagcttttg attttaacga cttttaacga 900 caacttgaga agatcaaaaa acaactaatt attcgaaacg aggaattcat ggcttacaga 960 aagagaggtg ctaagagaga ggacttgcca caacagaacg agagattgca agagaaagag 1020 atcgagaaca acactgacgt tactatggaa aacaagaaca agaacaaaaa caacaataga 1080 aagcagcagt tgtccgacaa ggttttgtcc cagaaagaag agatcatcac tgacgttcag 1140 gacgacatca agatcgctga cgaagttaag aagtcctcca aagaagagtc caagcagttg 1200 ttggagatct tgaaaacaaa agaggaccac cagaaagagg ttcagtacga gatcttgcaa 1260 aagactatcc caactttcga gccaaaagag tccatcttga agaagttgga ggacatcaag 1320 ccagagcagg ctaagaaaca gatgaagttg ttcagaatct tcgagccaag acagttgcca 1380 atctacagag ctaacggtga gaaagaattg agaaacagat ggtactggaa gttgaagaaa 1440 gacactttgc cagacggtga ctacgacgtt agagagtact tcttgaactt gtacgaccag 1500 atcttgatcg agatgccaga ctacttgttg ttgaaggaca tggctgttga gaacaagaac 1560 tccagagatg ctggtaaggt tgttgactcc gagactgcta gaatctgtga cgctattttc 1620 caggacgaag agactgaggg tgttattaga agattcattg ctgacatgag acagcaggtt 1680 caggctgaca gaaacatcgt taactaccca tccatcttgc acccaatcga ccacgctttc 1740 aacgagtact ttttgaacca ccagttggtt gagccattga acaacgagat catcttcaac 1800 tacatccctg agagaatcag aaacgacgtt aattacatct tgaacatgga catgaacttg 1860 ccatccactg ctagatatat cagaccaaac ttgttgcagg acagattgaa cttgcacgac 1920 aacttcgaat ccttgtggga cactatcact acttccaact acatcttggc tagatccgtt 1980 gttccagact tgaaagagaa agagttggtt tccactgagg ctcagatcca gaagatgtcc 2040 caagacttgc aattggaggc tttgactatc cagtccgaga ctcaattctt ggctggtatt 2100 aactcccagg ctgctaacga ctgtttcaag actttgatcg ctgctatgtt gtcccagaga 2160 actatgtcct tggacttcgt tactacaaac tacatgtcct tgatctccgg tatgtggttg 2220 ttgactgtta tcccaaacga catgttcttg agagaatcct tggttgcttg tgagttggct 2280 atcatcaaca ctatcgttta cccagctttc ggtatgcaga gaatgcacta cagaaacggt 2340 gacccacaaa ctccattcca gattgctgag cagcagatcc agaacttcca agttgctaac 2400 tggttgcact tcatcaacaa caacagattc agacaggttg ttatcgacgg tgttttgaac 2460 cagactttga acgacaacat cagaaacggt caggttatca accagttgat ggaagctttg 2520 atgcagttgt ccagacagca gttcccaact atgccagttg actacaagag atccatccag 2580 agaggtatct tgttgttgtc caacagattg ggtcagttgg ttgacttgac tagacttttg 2640 tcctacaact acgagacttt gatggcttgt atcactatga acatgcagca cgttcagact 2700 ttgactactg agagattgca gttgacttcc gttacttcct tgtgtatgtt gatcggtaac 2760 actactgtta ttccatcccc acagactttg ttccactact acaacgttaa tgttaacttc 2820 cactccaact acaacgagag aatcaacgac gctgttgcta tcatcactgc tgctaataga 2880 ttgaacttgt accaaaagaa gatgaagtcc atcgttgagg atttcttgaa gagattgcag 2940 atcttcgacg ttccaagagt tccagacgac cagatgtaca gattgagaga cagattgaga 3000 cttttgccag ttgagagaag aagattggac atcttcaact tgatcttgat gaacatggaa 3060 cagatcgaga gagcttccga caagattgct cagggtgtta tcattgctta cagagatatg 3120 cagttggagc gtgatgagat gtacggtttc gttaacattg ctagaaactt ggacggttac 3180 cagcagatca acttggaaga gttgatgaga actggtgact acggtcagat cactaacatg 3240 ttgttgaaca accagccagt tgctttggtt ggtgctttgc ctttcgttac tgactcctcc 3300 gttatctcct tgatcgctaa gttggacgct actgttttcg ctcagatcgt taagttgaga 3360 aaggttgaca ctttgaagcc aatcttgtac aaaatcaact ccgactccaa cgacttctac 3420 ttggttgcta actacgactg gatcccaact tccactacta aggtttacaa gcaggttcca 3480 cagccattcg acttcagagc ttctatgcac atgttgactt ccaacttgac tttcactgtt 3540 tactccgact tgttgtcctt cgtttccgct gacactgttg agcctattaa cgctatcgct 3600 ttcgacaaca tgagaatcat gaacgagttg ctcgagccgc ggcggccgcc agcttacgta 3660 gaacaaaaac tcatctcaga agaggatctg aatagcgccg tcgaccatca tcatcatcat 3720 cattgagttt gtagccttag acatgactgt tcctcagttc aagttgggca cttacgagaa 3780 gaccggtctt gctagattct aatcaagagg atgtcagaat gccatttgcc tgagagatgc 3840 aggcttcatt tttgatactt ttttatttgt aacctatata gtataggatt ttttttgtca 3900 ttttgtttct tctcgtacga gcttgctcct gatcagccta tctcgcagct gatgaatatc 3960 ttgtggtagg ggtttgggaa aatcattcga gtttgatgtt tttcttggta tttcccactc 4020 ctcttcagag tacagaagat taagtgagac cttcgtttgt gcggatcccc cacacaccat 4080 agcttcaaaa tgtttctact ccttttttac tcttccagat tttctcggac tccgcgcatc 4140 gccgtaccac ttcaaaacac ccaagcacag catactaaat tttccctctt tcttcctcta 4200 gggtgtcgtt aattacccgt actaaaggtt tggaaaagaa aaaagagacc gcctcgtttc 4260 tttttcttcg tcgaaaaagg caataaaaat ttttatcacg tttctttttc ttgaaatttt 4320 tttttttagt ttttttctct ttcagtgacc tccattgata tttaagttaa taaacggtct 4380 tcaatttctc aagtttcagt ttcatttttc ttgttctatt acaacttttt ttacttcttg 4440 ttcattagaa agaaagcata gcaatctaat ctaaggggcg gtgttgacaa ttaatcatcg 4500 gcatagtata tcggcatagt ataatacgac aaggtgagga actaaaccat ggccaagcct 4560 ttgtctcaag aagaatccac cctcattgaa agagcaacgg ctacaatcaa cagcatcccc 4620 atctctgaag actacagcgt cgccagcgca gctctctcta gcgacggccg catcttcact 4680 ggtgtcaatg tatatcattt tactggggga ccttgtgcag aactcgtggt gctgggcact 4740 gctgctgctg cggcagctgg caacctgact tgtatcgtcg cgatcggaaa tgagaacagg 4800 ggcatcttga gcccctgcgg acggtgccga caggtgcttc tcgatctgca tcctgggatc 4860 aaagccatag tgaaggacag tgatggacag ccgacggcag ttgggattcg tgaattgctg 4920 ccctctggtt atgtgtggga gggctaagca cttcgtggcc gaggagcagg actgacacgt 4980 ccgacggcgg cccacgggtc ccaggcctcg gagatccgtc ccccttttcc tttgtcgata 5040 tcatgtaatt agttatgtca cgcttacatt cacgccctcc ccccacatcc gctctaaccg 5100 aaaaggaagg agttagacaa cctgaagtct aggtccctat ttattttttt atagttatgt 5160 tagtattaag aacgttattt atatttcaaa tttttctttt ttttctgtac agacgcgtgt 5220 acgcatgtaa cattatactg aaaaccttgc ttgagaaggt tttgggacgc tcgaaggctt 5280 taatttgcaa gctggagacc aacatgtgag caaaaggcca gcaaaaggcc aggaaccgta 5340 aaaaggccgc gttgctggcg tttttccata ggctccgccc ccctgacgag catcacaaaa 5400 atcgacgctc aagtcagagg tggcgaaacc cgacaggact ataaagatac caggcgtttc 5460 cccctggaag ctccctcgtg cgctctcctg ttccgaccct gccgcttacc ggatacctgt 5520 ccgcctttct cccttcggga agcgtggcgc tttctcaatg ctcacgctgt aggtatctca 5580 gttcggtgta ggtcgttcgc tccaagctgg gctgtgtgca cgaacccccc gttcagcccg 5640 accgctgcgc cttatccggt aactatcgtc ttgagtccaa cccggtaaga cacgacttat 5700 cgccactggc agcagccact ggtaacagga ttagcagagc gaggtatgta ggcggtgcta 5760 cagagttctt gaagtggtgg cctaactacg gctacactag aaggacagta tttggtatct 5820 gcgctctgct gaagccagtt accttcggaa aaagagttgg tagctcttga tccggcaaac 5880 aaaccaccgc tggtagcggt ggtttttttg tttgcaagca gcagattacg cgcagaaaaa 5940 aaggatctca agaagatcct ttgatctttt ctacggggtc tgacgctcag tggaacgaaa 6000 actcacgtta agggattttg gtcatgagat c 6031 <210> 2 <211> 4488 <212> DNA <213> Artificial Sequence <220> <223> pPICZ-CAU200 VP6 <400> 2 agatctaaca tccaaagacg aaaggttgaa tgaaaccttt ttgccatccg acatccacag 60 gtccattctc acacataagt gccaaacgca acaggagggg atacactagc agcagaccgt 120 tgcaaacgca ggacctccac tcctcttctc ctcaacaccc acttttgcca tcgaaaaacc 180 agcccagtta ttgggcttga ttggagctcg ctcattccaa ttccttctat taggctacta 240 acaccatgac tttattagcc tgtctatcct ggcccccctg gcgaggttca tgtttgttta 300 tttccgaatg caacaagctc cgcattacac ccgaacatca ctccagatga gggctttctg 360 agtgtggggt caaatagttt catgttcccc aaatggccca aaactgacag tttaaacgct 420 gtcttggaac ctaatatgac aaaagcgtga tctcatccaa gatgaactaa gtttggttcg 480 ttgaaatgct aacggccagt tggtcaaaaa gaaacttcca aaagtcggca taccgtttgt 540 cttgtttggt attgattgac gaatgctcaa aaataatctc attaatgctt agcgcagtct 600 ctctatcgct tctgaacccc ggtgcacctg tgccgaaacg caaatgggga aacacccgct 660 ttttggatga ttatgcattg tctccacatt gtatgcttcc aagattctgg tgggaatact 720 gctgatagcc taacgttcat gatcaaaatt taactgttct aacccctact tgacagcaat 780 atataaacag aaggaagctg ccctgtctta aacctttttt tttatcatca ttattagctt 840 actttcataa ttgcgactgg ttccaattga caagcttttg attttaacga cttttaacga 900 caacttgaga agatcaaaaa acaactaatt attcgaaacg aggaattcat ggaagttttg 960 tactcattgt ccaagacttt gaaggacgct agagacaaga tcgttgaggg tactttgtac 1020 tccaacgttt ccgacttgat ccagcagttc aaccagatga tcgttactat gaacggtaac 1080 gacttccaga ctggtggtat cggtaacttg ccaatcagaa actggacttt cgacttcggt 1140 ttgttgggta ctactttgtt gaacttggac gctaactacg ttgagactgc tagaactact 1200 atcgagtact tcattgactt catcgacaac gtttgtatgg acgagatcgc tagagaatcc 1260 cagagaaacg gtgttgctcc acaatctgag gctttgagaa agttggctgg tatcaagttc 1320 aagagaatca acttcaacaa ctcctccgag tacatcgaga actggaactt gcagaacaga 1380 aggcagagaa ctggtttcgt tttccacaag ccaaacatct tcccttactc cgcttcattc 1440 actttgaaca gatctcagcc aatgcacgac aacttgatgg gtactatgtg gttgaacgct 1500 ggttccgaga ttcaggttgc tggtttcgat tactcctgtg ctttgaacgc tccagctaac 1560 attcaacagt tcgagcacat cgttcagttg cgtagagctt tgactactgc tactatcact 1620 ttgttgccag acgctgagag attctcattc ccaagagtta tcaactccgc tgacggtgct 1680 actacatggt tcttcaaccc aatcatcctt agaccaaaca acgttgaggt tgagttcttg 1740 ttgaacggtc agatcatcaa cacttaccag gctagattcg gtactattat cgctagaaac 1800 ttcgacacta tcagattgtc cttccagttg atgaggccac caaacatgac tccagctgtt 1860 aacgctttgt tcccacaagc tcaaccattc caacaccacg ctactgttgg tttgactttg 1920 agaatcgagt ccgctgtttg tgagtccgtt ttggctgatg ctaacgagac tttgttggct 1980 aacgttactg ctgttagaca agagtacgct atcccagttg gtccagtttt tccaccaggt 2040 atgaactgga ctgagttgat cactaactac tccccatcca gagaggacaa cttgcagaga 2100 gttttcactg ttgcttccat cagatccatg ttgatcaagc tcgagccgcg gcggccgcca 2160 gcttacgtag aacaaaaact catctcagaa gaggatctga atagcgccgt cgaccatcat 2220 catcatcatc attgagtttg tagccttaga catgactgtt cctcagttca agttgggcac 2280 ttacgagaag accggtcttg ctagattcta atcaagagga tgtcagaatg ccatttgcct 2340 gagagatgca ggcttcattt ttgatacttt tttatttgta acctatatag tataggattt 2400 tttttgtcat tttgtttctt ctcgtacgag cttgctcctg atcagcctat ctcgcagctg 2460 atgaatatct tgtggtaggg gtttgggaaa atcattcgag tttgatgttt ttcttggtat 2520 ttcccactcc tcttcagagt acagaagatt aagtgagacc ttcgtttgtg cggatccccc 2580 acacaccata gcttcaaaat gtttctactc cttttttact cttccagatt ttctcggact 2640 ccgcgcatcg ccgtaccact tcaaaacacc caagcacagc atactaaatt ttccctcttt 2700 cttcctctag ggtgtcgtta attacccgta ctaaaggttt ggaaaagaaa aaagagaccg 2760 cctcgtttct ttttcttcgt cgaaaaaggc aataaaaatt tttatcacgt ttctttttct 2820 tgaaattttt ttttttagtt tttttctctt tcagtgacct ccattgatat ttaagttaat 2880 aaacggtctt caatttctca agtttcagtt tcatttttct tgttctatta caactttttt 2940 tacttcttgt tcattagaaa gaaagcatag caatctaatc taaggggcgg tgttgacaat 3000 taatcatcgg catagtatat cggcatagta taatacgaca aggtgaggaa ctaaaccatg 3060 gccaagttga ccagtgccgt tccggtgctc accgcgcgcg acgtcgccgg agcggtcgag 3120 ttctggaccg accggctcgg gttctcccgg gacttcgtgg aggacgactt cgccggtgtg 3180 gtccgggacg acgtgaccct gttcatcagc gcggtccagg accaggtggt gccggacaac 3240 accctggcct gggtgtgggt gcgcggcctg gacgagctgt acgccgagtg gtcggaggtc 3300 gtgtccacga acttccggga cgcctccggg ccggccatga ccgagatcgg cgagcagccg 3360 tgggggcggg agttcgccct gcgcgacccg gccggcaact gcgtgcactt cgtggccgag 3420 gagcaggact gacacgtccg acggcggccc acgggtccca ggcctcggag atccgtcccc 3480 cttttccttt gtcgatatca tgtaattagt tatgtcacgc ttacattcac gccctccccc 3540 cacatccgct ctaaccgaaa aggaaggagt tagacaacct gaagtctagg tccctattta 3600 tttttttata gttatgttag tattaagaac gttatttata tttcaaattt ttcttttttt 3660 tctgtacaga cgcgtgtacg catgtaacat tatactgaaa accttgcttg agaaggtttt 3720 gggacgctcg aaggctttaa tttgcaagct ggagaccaac atgtgagcaa aaggccagca 3780 aaaggccagg aaccgtaaaa aggccgcgtt gctggcgttt ttccataggc tccgcccccc 3840 tgacgagcat cacaaaaatc gacgctcaag tcagaggtgg cgaaacccga caggactata 3900 aagataccag gcgtttcccc ctggaagctc cctcgtgcgc tctcctgttc cgaccctgcc 3960 gcttaccgga tacctgtccg cctttctccc ttcgggaagc gtggcgcttt ctcaatgctc 4020 acgctgtagg tatctcagtt cggtgtaggt cgttcgctcc aagctgggct gtgtgcacga 4080 accccccgtt cagcccgacc gctgcgcctt atccggtaac tatcgtcttg agtccaaccc 4140 ggtaagacac gacttatcgc cactggcagc agccactggt aacaggatta gcagagcgag 4200 gtatgtaggc ggtgctacag agttcttgaa gtggtggcct aactacggct acactagaag 4260 gacagtattt ggtatctgcg ctctgctgaa gccagttacc ttcggaaaaa gagttggtag 4320 ctcttgatcc ggcaaacaaa ccaccgctgg tagcggtggt ttttttgttt gcaagcagca 4380 gattacgcgc agaaaaaaag gatctcaaga agatcctttg atcttttcta cggggtctga 4440 cgctcagtgg aacgaaaact cacgttaagg gattttggtc atgagatc 4488 <210> 3 <211> 9985 <212> DNA <213> Artificial Sequence <220> <223> pPIC3.5K-CAU200 VP7 <400> 3 agatctaaca tccaaagacg aaaggttgaa tgaaaccttt ttgccatccg acatccacag 60 gtccattctc acacataagt gccaaacgca acaggagggg atacactagc agcagaccgt 120 tgcaaacgca ggacctccac tcctcttctc ctcaacaccc acttttgcca tcgaaaaacc 180 agcccagtta ttgggcttga ttggagctcg ctcattccaa ttccttctat taggctacta 240 acaccatgac tttattagcc tgtctatcct ggcccccctg gcgaggttca tgtttgttta 300 tttccgaatg caacaagctc cgcattacac ccgaacatca ctccagatga gggctttctg 360 agtgtggggt caaatagttt catgttcccc aaatggccca aaactgacag tttaaacgct 420 gtcttggaac ctaatatgac aaaagcgtga tctcatccaa gatgaactaa gtttggttcg 480 ttgaaatgct aacggccagt tggtcaaaaa gaaacttcca aaagtcgcca taccgtttgt 540 cttgtttggt attgattgac gaatgctcaa aaataatctc attaatgctt agcgcagtct 600 ctctatcgct tctgaacccc ggtgcacctg tgccgaaacg caaatgggga aacacccgct 660 ttttggatga ttatgcattg tctccacatt gtatgcttcc aagattctgg tgggaatact 720 gctgatagcc taacgttcat gatcaaaatt taactgttct aacccctact tgacagcaat 780 atataaacag aaggaagctg ccctgtctta aacctttttt tttatcatca ttattagctt 840 actttcataa ttgcgactgg ttccaattga caagcttttg attttaacga cttttaacga 900 caacttgaga agatcaaaaa acaactaatt attcgaagga tccatgtacg gtatcgagta 960 cactactatc ttgattttct tgatctccat catcttgttg aactacatct tgaagtccgt 1020 tactagaatc atggactaca tcatctacag attcttgttg atctccgttg ctttgttcgc 1080 tttgactaag gctcagaact acggtttgaa catcccaatc actggttcca tggacactgt 1140 ttactccaac tccactcaag aagaggtttt cttgacttcc actttgtgtt tgtactaccc 1200 aactgaggct tccactcaga tttctgacgg tgagtggaaa gaatccttgt cccagatgtt 1260 cttgactaag ggttggccaa ctggttccgt ttacttcaaa gagtactcca acatcgttga 1320 cttctccgtt gacccacagt tgtactgtga ctacaacttg gttttgatga agtacgacca 1380 gaacttggag ttggacatgt ctgagttggc tgacttgatc ttgaacgagt ggttgtgtaa 1440 cccaatggac atcactttgt actactacca gcaatccggt gagtccaaca agtggatttc 1500 tatgggttcc tcctgtactg ttaaggtttg tccattgaac actcagactt tgggtatcgg 1560 ttgtcagact acaaacgttg actccttcga gactgttgct gagaacgaga agttggctat 1620 cgttgacgtt gttgacggta tcaaccacaa gatcaacttg actactacta cttgtactat 1680 cagaaactgt aagaagttgg gtccaagaga gaacgttgct gttatccaag ttggtggttc 1740 caacgttttg gacatcactg ctgacccaac tacaaaccca cagatcgaga gaatgatgag 1800 agttaactgg aagagatggt ggcaggtttt ctacactatc gttgactaca tcaaccagat 1860 cgttcaggtt atgtccaaga gatccagatc cttgaactcc gctgctttct actacagagt 1920 tcatcatcat catcaccact aagcggccgc gaattaattc gccttagaca tgactgttcc 1980 tcagttcaag ttgggcactt acgagaagac cggtcttgct agattctaat caagaggatg 2040 tcagaatgcc atttgcctga gagatgcagg cttcattttt gatacttttt tatttgtaac 2100 ctatatagta taggattttt tttgtcattt tgtttcttct cgtacgagct tgctcctgat 2160 cagcctatct cgcagctgat gaatatcttg tggtaggggt ttgggaaaat cattcgagtt 2220 tgatgttttt cttggtattt cccactcctc ttcagagtac agaagattaa gtgagaagtt 2280 cgtttgtgca agcttatcga taagctttaa tgcggtagtt tatcacagtt aaattgctaa 2340 cgcagtcagg caccgtgtat gaaatctaac aatgcgctca tcgtcatcct cggcaccgtc 2400 accctggatg ctgtaggcat aggcttggtt atgccggtac tgccgggcct cttgcgggat 2460 atcgtccatt ccgacagcat cgccagtcac tatggcgtgc tgctagcgct atatgcgttg 2520 atgcaatttc tatgcgcacc cgttctcgga gcactgtccg accgctttgg ccgccgccca 2580 gtcctgctcg cttcgctact tggagccact atcgactacg cgatcatggc gaccacaccc 2640 gtcctgtgga tctatcgaat ctaaatgtaa gttaaaatct ctaaataatt aaataagtcc 2700 cagtttctcc atacgaacct taacagcatt gcggtgagca tctagacctt caacagcagc 2760 cagatccatc actgcttggc caatatgttt cagtccctca ggagttacgt cttgtgaagt 2820 gatgaacttc tggaaggttg cagtgttaac tccgctgtat tgacgggcat atccgtacgt 2880 tggcaaagtg tggttggtac cggaggagta atctccacaa ctctctggag agtaggcacc 2940 aacaaacaca gatccagcgt gttgtacttg atcaacataa gaagaagcat tctcgatttg 3000 caggatcaag tgttcaggag cgtactgatt ggacatttcc aaagcctgct cgtaggttgc 3060 aaccgatagg gttgtagagt gtgcaataca cttgcgtaca atttcaaccc ttggcaactg 3120 cacagcttgg ttgtgaacag catcttcaat tctggcaagc tccttgtctg tcatatcgac 3180 agccaacaga atcacctggg aatcaatacc atgttcagct tgagacagaa ggtctgaggc 3240 aacgaaatct ggatcagcgt atttatcagc aataactaga acttcagaag gcccagcagg 3300 catgtcaata ctacacaggg ctgatgtgtc attttgaacc atcatcttgg cagcagtaac 3360 gaactggttt cctggaccaa atattttgtc acacttagga acagtttctg ttccgtaagc 3420 catagcagct actgcctggg cgcctcctgc tagcacgata cacttagcac caaccttgtg 3480 ggcaacgtag atgacttctg gggtaagggt accatccttc ttaggtggag atgcaaaaac 3540 aatttctttg caaccagcaa ctttggcagg aacacccagc atcagggaag tggaaggcag 3600 aattgcggtt ccaccaggaa tatagaggcc aactttctca ataggtcttg caaaacgaga 3660 gcagactaca ccagggcaag tctcaacttg caacgtctcc gttagttgag cttcatggaa 3720 tttcctgacg ttatctatag agagatcaat ggctctctta acgttatctg gcaattgcat 3780 aagttcctct gggaaaggag cttctaacac aggtgtcttc aaagcgactc catcaaactt 3840 ggcagttagt tctaaaaggg ctttgtcacc attttgacga acattgtcga caattggttt 3900 gactaattcc ataatctgtt ccgttttctg gataggacga cgaagggcat cttcaatttc 3960 ttgtgaggag gccttagaaa cgtcaatttt gcacaattca atacgacctt cagaagggac 4020 ttctttaggt ttggattctt ctttaggttg ttccttggtg tatcctggct tggcatctcc 4080 tttccttcta gtgaccttta gggacttcat atccaggttt ctctccacct cgtccaacgt 4140 cacaccgtac ttggcacatc taactaatgc aaaataaaat aagtcagcac attcccaggc 4200 tatatcttcc ttggatttag cttctgcaag ttcatcagct tcctccctaa ttttagcgtt 4260 caacaaaact tcgtcgtcaa ataaccgttt ggtataagaa ccttctggag cattgctctt 4320 acgatcccac aaggtggctt ccatggctct aagacccttt gattggccaa aacaggaagt 4380 gcgttccaag tgacagaaac caacacctgt ttgttcaacc acaaatttca agcagtctcc 4440 atcacaatcc aattcgatac ccagcaactt ttgagttgct ccagatgtag cacctttata 4500 ccacaaaccg tgacgacgag attggtagac tccagtttgt gtccttatag cctccggaat 4560 agactttttg gacgagtaca ccaggcccaa cgagtaatta gaagagtcag ccaccaaagt 4620 agtgaataga ccatcggggc ggtcagtagt caaagacgcc aacaaaattt cactgacagg 4680 gaactttttg acatcttcag aaagttcgta ttcagtagtc aattgccgag catcaataat 4740 ggggattata ccagaagcaa cagtggaagt cacatctacc aactttgcgg tctcagaaaa 4800 agcataaaca gttctactac cgccattagt gaaacttttc aaatcgccca gtggagaaga 4860 aaaaggcaca gcgatactag cattagcggg caaggatgca actttatcaa ccagggtcct 4920 atagataacc ctagcgcctg ggatcatcct ttggacaact ctttctgcca aatctaggtc 4980 caaaatcact tcattgatac cattattgta caacttgagc aagttgtcga tcagctcctc 5040 aaattggtcc tctgtaacgg atgactcaac ttgcacatta acttgaagct cagtcgattg 5100 agtgaacttg atcaggttgt gcagctggtc agcagcatag ggaaacacgg cttttcctac 5160 caaactcaag gaattatcaa actctgcaac acttgcgtat gcaggtagca agggaaatgt 5220 catacttgaa gtcggacagt gagtgtagtc ttgagaaatt ctgaagccgt atttttatta 5280 tcagtgagtc agtcatcagg agatcctcta cgccggacgc atcgtggccg acctgcaggg 5340 gggggggggg cgctgaggtc tgcctcgtga agaaggtgtt gctgactcat accaggcctg 5400 aatcgcccca tcatccagcc agaaagtgag ggagccacgg ttgatgagag ctttgttgta 5460 ggtggaccag ttggtgattt tgaacttttg ctttgccacg gaacggtctg cgttgtcggg 5520 aagatgcgtg atctgatcct tcaactcagc aaaagttcga tttattcaac aaagccgccg 5580 tcccgtcaag tcagcgtaat gctctgccag tgttacaacc aattaaccaa ttctgattag 5640 aaaaactcat cgagcatcaa atgaaactgc aatttattca tatcaggatt atcaatacca 5700 tatttttgaa aaagccgttt ctgtaatgaa ggagaaaact caccgaggca gttccatagg 5760 atggcaagat cctggtatcg gtctgcgatt ccgactcgtc caacatcaat acaacctatt 5820 aatttcccct cgtcaaaaat aaggttatca agtgagaaat caccatgagt gacgactgaa 5880 tccggtgaga atggcaaaag cttatgcatt tctttccaga cttgttcaac aggccagcca 5940 ttacgctcgt catcaaaatc actcgcatca accaaaccgt tattcattcg tgattgcgcc 6000 tgagcgagac gaaatacgcg atcgctgtta aaaggacaat tacaaacagg aatcgaatgc 6060 aaccggcgca ggaacactgc cagcgcatca acaatatttt cacctgaatc aggatattct 6120 tctaatacct ggaatgctgt tttcccgggg atcgcagtgg tgagtaacca tgcatcatca 6180 ggagtacgga taaaatgctt gatggtcgga agaggcataa attccgtcag ccagtttagt 6240 ctgaccatct catctgtaac atcattggca acgctacctt tgccatgttt cagaaacaac 6300 tctggcgcat cgggcttccc atacaatcga tagattgtcg cacctgattg cccgacatta 6360 tcgcgagccc atttataccc atataaatca gcatccatgt tggaatttaa tcgcggcctc 6420 gagcaagacg tttcccgttg aatatggctc ataacacccc ttgtattact gtttatgtaa 6480 gcagacagtt ttattgttca tgatgatata tttttatctt gtgcaatgta acatcagaga 6540 ttttgagaca caacgtggct ttcccccccc cccctgcagg tcggcatcac cggcgccaca 6600 ggtgcggttg ctggcgccta tatcgccgac atcaccgatg gggaagatcg ggctcgccac 6660 ttcgggctca tgagcgcttg tttcggcgtg ggtatggtgg caggccccgt ggccggggga 6720 ctgttgggcg ccatctcctt gcatgcacca ttccttgcgg cggcggtgct caacggcctc 6780 aacctactac tgggctgctt cctaatgcag gagtcgcata agggagagcg tcgagtatct 6840 atgattggaa gtatgggaat ggtgataccc gcattcttca gtgtcttgag gtctcctatc 6900 agattatgcc caactaaagc aaccggagga ggagatttca tggtaaattt ctctgacttt 6960 tggtcatcag tagactcgaa ctgtgagact atctcggtta tgacagcaga aatgtccttc 7020 ttggagacag taaatgaagt cccaccaata aagaaatcct tgttatcagg aacaaacttc 7080 ttgtttcgaa ctttttcggt gccttgaact ataaaatgta gagtggatat gtcgggtagg 7140 aatggagcgg gcaaatgctt accttctgga ccttcaagag gtatgtaggg tttgtagata 7200 ctgatgccaa cttcagtgac aacgttgcta tttcgttcaa accattccga atccagagaa 7260 atcaaagttg tttgtctact attgatccaa gccagtgcgg tcttgaaact gacaatagtg 7320 tgctcgtgtt ttgaggtcat ctttgtatga ataaatctag tctttgatct aaataatctt 7380 gacgagccaa ggcgataaat acccaaatct aaaactcttt taaaacgtta aaaggacaag 7440 tatgtctgcc tgtattaaac cccaaatcag ctcgtagtct gatcctcatc aacttgaggg 7500 gcactatctt gttttagaga aatttgcgga gatgcgatat cgagaaaaag gtacgctgat 7560 tttaaacgtg aaatttatct caagatctct gcctcgcgcg tttcggtgat gacggtgaaa 7620 acctctgaca catgcagctc ccggagacgg tcacagcttg tctgtaagcg gatgccggga 7680 gcagacaagc ccgtcagggc gcgtcagcgg gtgttggcgg gtgtcggggc gcagccatga 7740 cccagtcacg tagcgatagc ggagtgtata ctggcttaac tatgcggcat cagagcagat 7800 tgtactgaga gtgcaccata tgcggtgtga aataccgcac agatgcgtaa ggagaaaata 7860 ccgcatcagg cgctcttccg cttcctcgct cactgactcg ctgcgctcgg tcgttcggct 7920 gcggcgagcg gtatcagctc actcaaaggc ggtaatacgg ttatccacag aatcagggga 7980 taacgcagga aagaacatgt gagcaaaagg ccagcaaaag gccaggaacc gtaaaaaggc 8040 cgcgttgctg gcgtttttcc ataggctccg cccccctgac gagcatcaca aaaatcgacg 8100 ctcaagtcag aggtggcgaa acccgacagg actataaaga taccaggcgt ttccccctgg 8160 aagctccctc gtgcgctctc ctgttccgac cctgccgctt accggatacc tgtccgcctt 8220 tctcccttcg ggaagcgtgg cgctttctca atgctcacgc tgtaggtatc tcagttcggt 8280 gtaggtcgtt cgctccaagc tgggctgtgt gcacgaaccc cccgttcagc ccgaccgctg 8340 cgccttatcc ggtaactatc gtcttgagtc caacccggta agacacgact tatcgccact 8400 ggcagcagcc actggtaaca ggattagcag agcgaggtat gtaggcggtg ctacagagtt 8460 cttgaagtgg tggcctaact acggctacac tagaaggaca gtatttggta tctgcgctct 8520 gctgaagcca gttaccttcg gaaaaagagt tggtagctct tgatccggca aacaaaccac 8580 cgctggtagc ggtggttttt ttgtttgcaa gcagcagatt acgcgcagaa aaaaaggatc 8640 tcaagaagat cctttgatct tttctacggg gtctgacgct cagtggaacg aaaactcacg 8700 ttaagggatt ttggtcatga gattatcaaa aaggatcttc acctagatcc ttttaaatta 8760 aaaatgaagt tttaaatcaa tctaaagtat atatgagtaa acttggtctg acagttacca 8820 atgcttaatc agtgaggcac ctatctcagc gatctgtcta tttcgttcat ccatagttgc 8880 ctgactcccc gtcgtgtaga taactacgat acgggagggc ttaccatctg gccccagtgc 8940 tgcaatgata ccgcgagacc cacgctcacc ggctccagat ttatcagcaa taaaccagcc 9000 agccggaagg gccgagcgca gaagtggtcc tgcaacttta tccgcctcca tccagtctat 9060 taattgttgc cgggaagcta gagtaagtag ttcgccagtt aatagtttgc gcaacgttgt 9120 tgccattgct gcaggcatcg tggtgtcacg ctcgtcgttt ggtatggctt cattcagctc 9180 cggttcccaa cgatcaaggc gagttacatg atcccccatg ttgtgcaaaa aagcggttag 9240 ctccttcggt cctccgatcg ttgtcagaag taagttggcc gcagtgttat cactcatggt 9300 tatggcagca ctgcataatt ctcttactgt catgccatcc gtaagatgct tttctgtgac 9360 tggtgagtac tcaaccaagt cattctgaga atagtgtatg cggcgaccga gttgctcttg 9420 cccggcgtca acacgggata ataccgcgcc acatagcaga actttaaaag tgctcatcat 9480 tggaaaacgt tcttcggggc gaaaactctc aaggatctta ccgctgttga gatccagttc 9540 gatgtaaccc actcgtgcac ccaactgatc ttcagcatct tttactttca ccagcgtttc 9600 tgggtgagca aaaacaggaa ggcaaaatgc cgcaaaaaag ggaataaggg cgacacggaa 9660 atgttgaata ctcatactct tcctttttca atattattga agcatttatc agggttattg 9720 tctcatgagc ggatacatat ttgaatgtat ttagaaaaat aaacaaatag gggttccgcg 9780 cacatttccc cgaaaagtgc cacctgacgt ctaagaaacc attattatca tgacattaac 9840 ctataaaaat aggcgtatca cgaggccctt tcgtcttcaa gaattaattc tcatgtttga 9900 cagcttatca tcgataagct gactcatgtt ggtattgtga aatagacgca gatcgggaac 9960 actgaaaaat aacagttatt attcg 9985 <210> 4 <211> 2694 <212> DNA <213> Artificial Sequence <220> <223> CAU200 VP2co <400> 4 gaattcatgg cttacagaaa gagaggtgct aagagagagg acttgccaca acagaacgag 60 agattgcaag agaaagagat cgagaacaac actgacgtta ctatggaaaa caagaacaag 120 aacaaaaaca acaatagaaa gcagcagttg tccgacaagg ttttgtccca gaaagaagag 180 atcatcactg acgttcagga cgacatcaag atcgctgacg aagttaagaa gtcctccaaa 240 gaagagtcca agcagttgtt ggagatcttg aaaacaaaag aggaccacca gaaagaggtt 300 cagtacgaga tcttgcaaaa gactatccca actttcgagc caaaagagtc catcttgaag 360 aagttggagg acatcaagcc agagcaggct aagaaacaga tgaagttgtt cagaatcttc 420 gagccaagac agttgccaat ctacagagct aacggtgaga aagaattgag aaacagatgg 480 tactggaagt tgaagaaaga cactttgcca gacggtgact acgacgttag agagtacttc 540 ttgaacttgt acgaccagat cttgatcgag atgccagact acttgttgtt gaaggacatg 600 gctgttgaga acaagaactc cagagatgct ggtaaggttg ttgactccga gactgctaga 660 atctgtgacg ctattttcca ggacgaagag actgagggtg ttattagaag attcattgct 720 gacatgagac agcaggttca ggctgacaga aacatcgtta actacccatc catcttgcac 780 ccaatcgacc acgctttcaa cgagtacttt ttgaaccacc agttggttga gccattgaac 840 aacgagatca tcttcaacta catccctgag agaatcagaa acgacgttaa ttacatcttg 900 aacatggaca tgaacttgcc atccactgct agatatatca gaccaaactt gttgcaggac 960 agattgaact tgcacgacaa cttcgaatcc ttgtgggaca ctatcactac ttccaactac 1020 atcttggcta gatccgttgt tccagacttg aaagagaaag agttggtttc cactgaggct 1080 cagatccaga agatgtccca agacttgcaa ttggaggctt tgactatcca gtccgagact 1140 caattcttgg ctggtattaa ctcccaggct gctaacgact gtttcaagac tttgatcgct 1200 gctatgttgt cccagagaac tatgtccttg gacttcgtta ctacaaacta catgtccttg 1260 atctccggta tgtggttgtt gactgttatc ccaaacgaca tgttcttgag agaatccttg 1320 gttgcttgtg agttggctat catcaacact atcgtttacc cagctttcgg tatgcagaga 1380 atgcactaca gaaacggtga cccacaaact ccattccaga ttgctgagca gcagatccag 1440 aacttccaag ttgctaactg gttgcacttc atcaacaaca acagattcag acaggttgtt 1500 atcgacggtg ttttgaacca gactttgaac gacaacatca gaaacggtca ggttatcaac 1560 cagttgatgg aagctttgat gcagttgtcc agacagcagt tcccaactat gccagttgac 1620 tacaagagat ccatccagag aggtatcttg ttgttgtcca acagattggg tcagttggtt 1680 gacttgacta gacttttgtc ctacaactac gagactttga tggcttgtat cactatgaac 1740 atgcagcacg ttcagacttt gactactgag agattgcagt tgacttccgt tacttccttg 1800 tgtatgttga tcggtaacac tactgttatt ccatccccac agactttgtt ccactactac 1860 aacgttaatg ttaacttcca ctccaactac aacgagagaa tcaacgacgc tgttgctatc 1920 atcactgctg ctaatagatt gaacttgtac caaaagaaga tgaagtccat cgttgaggat 1980 ttcttgaaga gattgcagat cttcgacgtt ccaagagttc cagacgacca gatgtacaga 2040 ttgagagaca gattgagact tttgccagtt gagagaagaa gattggacat cttcaacttg 2100 atcttgatga acatggaaca gatcgagaga gcttccgaca agattgctca gggtgttatc 2160 attgcttaca gagatatgca gttggagcgt gatgagatgt acggtttcgt taacattgct 2220 agaaacttgg acggttacca gcagatcaac ttggaagagt tgatgagaac tggtgactac 2280 ggtcagatca ctaacatgtt gttgaacaac cagccagttg ctttggttgg tgctttgcct 2340 ttcgttactg actcctccgt tatctccttg atcgctaagt tggacgctac tgttttcgct 2400 cagatcgtta agttgagaaa ggttgacact ttgaagccaa tcttgtacaa aatcaactcc 2460 gactccaacg acttctactt ggttgctaac tacgactgga tcccaacttc cactactaag 2520 gtttacaagc aggttccaca gccattcgac ttcagagctt ctatgcacat gttgacttcc 2580 aacttgactt tcactgttta ctccgacttg ttgtccttcg tttccgctga cactgttgag 2640 cctattaacg ctatcgcttt cgacaacatg agaatcatga acgagttgct cgag 2694 <210> 5 <211> 1203 <212> DNA <213> Artificial Sequence <220> <223> CAU200 VP6co <400> 5 gaattcatgg aagttttgta ctcattgtcc aagactttga aggacgctag agacaagatc 60 gttgagggta ctttgtactc caacgtttcc gacttgatcc agcagttcaa ccagatgatc 120 gttactatga acggtaacga cttccagact ggtggtatcg gtaacttgcc aatcagaaac 180 tggactttcg acttcggttt gttgggtact actttgttga acttggacgc taactacgtt 240 gagactgcta gaactactat cgagtacttc attgacttca tcgacaacgt ttgtatggac 300 gagatcgcta gagaatccca gagaaacggt gttgctccac aatctgaggc tttgagaaag 360 ttggctggta tcaagttcaa gagaatcaac ttcaacaact cctccgagta catcgagaac 420 tggaacttgc agaacagaag gcagagaact ggtttcgttt tccacaagcc aaacatcttc 480 ccttactccg cttcattcac tttgaacaga tctcagccaa tgcacgacaa cttgatgggt 540 actatgtggt tgaacgctgg ttccgagatt caggttgctg gtttcgatta ctcctgtgct 600 ttgaacgctc cagctaacat tcaacagttc gagcacatcg ttcagttgcg tagagctttg 660 actactgcta ctatcacttt gttgccagac gctgagagat tctcattccc aagagttatc 720 aactccgctg acggtgctac tacatggttc ttcaacccaa tcatccttag accaaacaac 780 gttgaggttg agttcttgtt gaacggtcag atcatcaaca cttaccaggc tagattcggt 840 actattatcg ctagaaactt cgacactatc agattgtcct tccagttgat gaggccacca 900 aacatgactc cagctgttaa cgctttgttc ccacaagctc aaccattcca acaccacgct 960 actgttggtt tgactttgag aatcgagtcc gctgtttgtg agtccgtttt ggctgatgct 1020 aacgagactt tgttggctaa cgttactgct gttagacaag agtacgctat cccagttggt 1080 ccagtttttc caccaggtat gaactggact gagttgatca ctaactactc cccatccaga 1140 gaggacaact tgcagagagt tttcactgtt gcttccatca gatccatgtt gatcaagctc 1200 gag 1203 <210> 6 <211> 990 <212> DNA <213> Artificial Sequence <220> <223> CAU200 VP7co <400> 6 gaattcatgt acggtatcga gtacactact atcttgattt tcttgatctc catcatcttg 60 ttgaactaca tcttgaagtc cgttactaga atcatggact acatcatcta cagattcttg 120 ttgatctccg ttgctttgtt cgctttgact aaggctcaga actacggttt gaacatccca 180 atcactggtt ccatggacac tgtttactcc aactccactc aagaagaggt tttcttgact 240 tccactttgt gtttgtacta cccaactgag gcttccactc agatttctga cggtgagtgg 300 aaagaatcct tgtcccagat gttcttgact aagggttggc caactggttc cgtttacttc 360 aaagagtact ccaacatcgt tgacttctcc gttgacccac agttgtactg tgactacaac 420 ttggttttga tgaagtacga ccagaacttg gagttggaca tgtctgagtt ggctgacttg 480 atcttgaacg agtggttgtg taacccaatg gacatcactt tgtactacta ccagcaatcc 540 ggtgagtcca acaagtggat ttctatgggt tcctcctgta ctgttaaggt ttgtccattg 600 aacactcaga ctttgggtat cggttgtcag actacaaacg ttgactcctt cgagactgtt 660 gctgagaacg agaagttggc tatcgttgac gttgttgacg gtatcaacca caagatcaac 720 ttgactacta ctacttgtac tatcagaaac tgtaagaagt tgggtccaag agagaacgtt 780 gctgttatcc aagttggtgg ttccaacgtt ttggacatca ctgctgaccc aactacaaac 840 ccacagatcg agagaatgat gagagttaac tggaagagat ggtggcaggt tttctacact 900 atcgttgact acatcaacca gatcgttcag gttatgtcca agagatccag atccttgaac 960 tccgctgctt tctactacag agttctcgag 990 <210> 7 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> AOX1 primer <400> 7 gcaaatggca ttctgacatc c 21 <210> 8 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> VP2 primer <400> 8 ccaggacgaa gagactgagg 20 <210> 9 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> VP6 primer <400> 9 caacagttcg agcacatcgt 20 <210> 10 <211> 23 <212> DNA <213> Artificial Sequence <220> <223> V7 primer <400> 10 cagttgtact gtgactacaa ctt 23 <110> Chung-Ang University Industry-Academy Cooperation Foundation <120> Method for Producing and Purifying Virus-Like Particle of          Rotavirus using Yeast strain <130> CAU20151894KR_MP15-100 <160> 10 <170> KoPatentin 3.0 <210> 1 <211> 6031 <212> DNA <213> Artificial Sequence <220> <223> pPIC6-CAU200 VP2 <400> 1 agatctaaca tccaaagacg aaaggttgaa tgaaaccttt ttgccatccg acatccacag 60 gtccattctc acacataagt gccaaacgca acaggagggg atacactagc agcagaccgt 120 tgcaaacgca ggacctccac tcctcttctc ctcaacaccc acttttgcca tcgaaaaacc 180 agcccagtta ttgggcttga ttggagctcg ctcattccaa ttccttctat taggctacta 240 acaccatgac tttattagcc tgtctatcct ggcccccctg gcgaggttca tgtttgttta 300 tttccgaatg caacaagctc cgcattacac ccgaacatca ctccagatga gggctttctg 360 agtgtggggt caaatagttt catgttcccc aaatggccca aaactgacag tttaaacgct 420 gtcttggaac ctaatatgac aaaagcgtga tctcatccaa gatgaactaa gtttggttcg 480 ttgaaatgct aacggccagt tggtcaaaaa gaaacttcca aaagtcggca taccgtttgt 540 cttgtttggt attgattgac gaatgctcaa aaataatctc attaatgctt agcgcagtct 600 ctctatcgct tctgaacccc ggtgcacctg tgccgaaacg caaatgggga aacacccgct 660 ttttggatga ttatgcattg tctccacatt gtatgcttcc aagattctgg tgggaatact 720 gctgatagcc taacgttcat gatcaaaatt taactgttct aacccctact tgacagcaat 780 atataaacag aaggaagctg ccctgtctta aacctttttt tttatcatca ttattagctt 840 actttcataa ttgcgactgg ttccaattga caagcttttg attttaacga cttttaacga 900 caacttgaga agatcaaaaa acaactaatt attcgaaacg aggaattcat ggcttacaga 960 aagagaggtg ctaagagaga ggacttgcca caacagaacg agagattgca agagaaagag 1020 atcgagaaca acactgacgt tactatggaa aacaagaaca agaacaaaaa caacaataga 1080 aagcagcagt tgtccgacaa ggttttgtcc cagaaagaag agatcatcac tgacgttcag 1140 gacgacatca agatcgctga cgaagttaag aagtcctcca aagaagagtc caagcagttg 1200 ttggagatct tgaaaacaaa agaggaccac cagaaagagg ttcagtacga gatcttgcaa 1260 aagactatcc caactttcga gccaaaagag tccatcttga agaagttgga ggacatcaag 1320 ccagagcagg ctaagaaaca gatgaagttg ttcagaatct tcgagccaag acagttgcca 1380 atctacagag ctaacggtga gaaagaattg agaaacagat ggtactggaa gttgaagaaa 1440 gacactttgc cagacggtga ctacgacgtt agagagtact tcttgaactt gtacgaccag 1500 atcttgatcg agatgccaga ctacttgttg ttgaaggaca tggctgttga gaacaagaac 1560 tccagagatg ctggtaaggt tgttgactcc gagactgcta gaatctgtga cgctattttc 1620 caggacgaag agactgaggg tgttattaga agattcattg ctgacatgag acagcaggtt 1680 caggctgaca gaaacatcgt taactaccca tccatcttgc acccaatcga ccacgctttc 1740 aacgagtact ttttgaacca ccagttggtt gagccattga acaacgagat catcttcaac 1800 tacatccctg agagaatcag aaacgacgtt aattacatct tgaacatgga catgaacttg 1860 ccatccactg ctagatatat cagaccaaac ttgttgcagg acagattgaa cttgcacgac 1920 aacttcgaat ccttgtggga cactatcact acttccaact acatcttggc tagatccgtt 1980 gttccagact tgaaagagaa agagttggtt tccactgagg ctcagatcca gaagatgtcc 2040 caagacttgc aattggaggc tttgactatc cagtccgaga ctcaattctt ggctggtatt 2100 aactcccagg ctgctaacga ctgtttcaag actttgatcg ctgctatgtt gtcccagaga 2160 actatgtcct tggacttcgt tactacaaac tacatgtcct tgatctccgg tatgtggttg 2220 ttgactgtta tcccaaacga catgttcttg agagaatcct tggttgcttg tgagttggct 2280 atcatcaaca ctatcgttta cccagctttc ggtatgcaga gaatgcacta cagaaacggt 2340 gacccacaaa ctccattcca gattgctgag cagcagatcc agaacttcca agttgctaac 2400 tggttgcact tcatcaacaa caacagattc agacaggttg ttatcgacgg tgttttgaac 2460 cagactttga acgacaacat cagaaacggt caggttatca accagttgat ggaagctttg 2520 atgcagttgt ccagacagca gttcccaact atgccagttg actacaagag atccatccag 2580 agaggtatct tgttgttgtc caacagattg ggtcagttgg ttgacttgac tagacttttg 2640 tcctacaact acgagacttt gatggcttgt atcactatga acatgcagca cgttcagact 2700 ttgactactg agagattgca gttgacttcc gttacttcct tgtgtatgtt gatcggtaac 2760 actactgtta ttccatcccc acagactttg ttccactact acaacgttaa tgttaacttc 2820 cactccaact acaacgagag aatcaacgac gctgttgcta tcatcactgc tgctaataga 2880 ttgaacttgt accaaaagaa gatgaagtcc atcgttgagg atttcttgaa gagattgcag 2940 atcttcgacg ttccaagagt tccagacgac cagatgtaca gattgagaga cagattgaga 3000 cttttgccag ttgagagaag aagattggac atcttcaact tgatcttgat gaacatggaa 3060 cagatcgaga gagcttccga caagattgct cagggtgtta tcattgctta cagagatatg 3120 cagttggagc gtgatgagat gtacggtttc gttaacattg ctagaaactt ggacggttac 3180 cagcagatca acttggaaga gttgatgaga actggtgact acggtcagat cactaacatg 3240 tggttgaaca accagccagt tgctttggtt ggtgctttgc ctttcgttac tgactcctcc 3300 gttatctcct tgatcgctaa gttggacgct actgttttcg ctcagatcgt taagttgaga 3360 aagtttgaca ctttgaagcc aatcttgtac aaaatcaact ccgactccaa cgacttctac 3420 ttggttgcta actacgactg gatcccaact tccactacta aggtttacaa gcaggttcca 3480 cagccattcg acttcagagc ttctatgcac atgttgactt ccaacttgac tttcactgtt 3540 tactccgact tgttgtcctt cgtttccgct gacactgttg agcctattaa cgctatcgct 3600 ttcgacaaca tgagaatcat gaacgagttg ctcgagccgc ggcggccgcc agcttacgta 3660 gaacaaaaac tcatctcaga agaggatctg aatagcgccg tcgaccatca tcatcatcat 3720 cattgagttt gtagccttag acatgactgt tcctcagttc aagttgggca cttacgagaa 3780 gaccggtctt gctagattct aatcaagagg atgtcagaat gccatttgcc tgagagatgc 3840 aggcttcatt tttgatactt ttttatttgt aacctatata gtataggatt ttttttgtca 3900 ttttgtttct tctcgtacga gcttgctcct gatcagccta tctcgcagct gatgaatatc 3960 ttgtggtagg ggtttgggaa aatcattcga gtttgatgtt tttcttggta tttcccactc 4020 ctcttcagag tacagaagat taagtgagac cttcgtttgt gcggatcccc cacacaccat 4080 agcttcaaaa tgtttctact ccttttttac tcttccagat tttctcggac tccgcgcatc 4140 gccgtaccac ttcaaaacac ccaagcacag catactaaat tttccctctt tcttcctcta 4200 gggtgtcgtt aattacccgt actaaaggtt tggaaaagaa aaaagagacc gcctcgtttc 4260 tttttcttcg tcgaaaaagg caataaaaat ttttatcacg tttctttttc ttgaaatttt 4320 tttttttagt ttttttctct ttcagtgacc tccattgata tttaagttaa taaacggtct 4380 tcaatttctc aagtttcagt ttcatttttc ttgttctatt acaacttttt ttacttcttg 4440 ttcattagaa agaaagcata gcaatctaat ctaaggggcg gtgttgacaa ttaatcatcg 4500 gcatagtata tcggcatagt ataatacgac aaggtgagga actaaaccat ggccaagcct 4560 ttgtctcaag aagaatccac cctcattgaa agagcaacgg ctacaatcaa cagcatcccc 4620 atctctgaag actacagcgt cgccagcgca gctctctcta gcgacggccg catcttcact 4680 ggtgtcaatg tatatcattt tactggggga ccttgtgcag aactcgtggt gctgggcact 4740 gctgctgctg cggcagctgg caacctgact tgtatcgtcg cgatcggaaa tgagaacagg 4800 ggcatcttga gcccctgcgg acggtgccga caggtgcttc tcgatctgca tcctgggatc 4860 aaagccatag tgaaggacag tgatggacag ccgacggcag ttgggattcg tgaattgctg 4920 ccctctggtt atgtgtggga gggctaagca cttcgtggcc gaggagcagg actgacacgt 4980 ccgacggcgg cccacgggtc ccaggcctcg gagatccgtc ccccttttcc tttgtcgata 5040 tcatgtaatt agttatgtca cgcttacatt cacgccctcc ccccacatcc gctctaaccg 5100 aaaaggaagg agttagacaa cctgaagtct aggtccctat ttattttttt atagttatgt 5160 tagtattaag aacgttattt atatttcaaa tttttctttt ttttctgtac agacgcgtgt 5220 acgcatgtaa cattatactg aaaaccttgc ttgagaaggt tttgggacgc tcgaaggctt 5280 taatttgcaa gctggagacc aacatgtgag caaaaggcca gcaaaaggcc aggaaccgta 5340 aaaaggccgc gttgctggcg tttttccata ggctccgccc ccctgacgag catcacaaaa 5400 atcgacgctc aagtcagagg tggcgaaacc cgacaggact ataaagatac caggcgtttc 5460 cccctggaag ctccctcgtg cgctctcctg ttccgaccct gccgcttacc ggatacctgt 5520 ccgcctttct cccttcggga agcgtggcgc tttctcaatg ctcacgctgt aggtatctca 5580 gttcggtgta ggtcgttcgc tccaagctgg gctgtgtgca cgaacccccc gttcagcccg 5640 accgctgcgc cttatccggt aactatcgtc ttgagtccaa cccggtaaga cacgacttat 5700 cgccactggc agcagccact ggtaacagga ttagcagagc gaggtatgta ggcggtgcta 5760 cagagttctt gaagtggtgg cctaactacg gctacactag aaggacagta tttggtatct 5820 gcgctctgct gaagccagtt accttcggaa aaagagttgg tagctcttga tccggcaaac 5880 aaaccaccgc tggtagcggt ggtttttttg tttgcaagca gcagattacg cgcagaaaaa 5940 aaggatctca agaagatcct ttgatctttt ctacggggtc tgacgctcag tggaacgaaa 6000 actcacgtta agggattttg gtcatgagat c 6031 <210> 2 <211> 4488 <212> DNA <213> Artificial Sequence <220> <223> pPICZ-CAU200 VP6 <400> 2 agatctaaca tccaaagacg aaaggttgaa tgaaaccttt ttgccatccg acatccacag 60 gtccattctc acacataagt gccaaacgca acaggagggg atacactagc agcagaccgt 120 tgcaaacgca ggacctccac tcctcttctc ctcaacaccc acttttgcca tcgaaaaacc 180 agcccagtta ttgggcttga ttggagctcg ctcattccaa ttccttctat taggctacta 240 acaccatgac tttattagcc tgtctatcct ggcccccctg gcgaggttca tgtttgttta 300 tttccgaatg caacaagctc cgcattacac ccgaacatca ctccagatga gggctttctg 360 agtgtggggt caaatagttt catgttcccc aaatggccca aaactgacag tttaaacgct 420 gtcttggaac ctaatatgac aaaagcgtga tctcatccaa gatgaactaa gtttggttcg 480 ttgaaatgct aacggccagt tggtcaaaaa gaaacttcca aaagtcggca taccgtttgt 540 cttgtttggt attgattgac gaatgctcaa aaataatctc attaatgctt agcgcagtct 600 ctctatcgct tctgaacccc ggtgcacctg tgccgaaacg caaatgggga aacacccgct 660 ttttggatga ttatgcattg tctccacatt gtatgcttcc aagattctgg tgggaatact 720 gctgatagcc taacgttcat gatcaaaatt taactgttct aacccctact tgacagcaat 780 atataaacag aaggaagctg ccctgtctta aacctttttt tttatcatca ttattagctt 840 actttcataa ttgcgactgg ttccaattga caagcttttg attttaacga cttttaacga 900 caacttgaga agatcaaaaa acaactaatt attcgaaacg aggaattcat ggaagttttg 960 tactcattgt ccaagacttt gaaggacgct agagacaaga tcgttgaggg tactttgtac 1020 tccaacgttt ccgacttgat ccagcagttc aaccagatga tcgttactat gaacggtaac 1080 gacttccaga ctggtggtat cggtaacttg ccaatcagaa actggacttt cgacttcggt 1140 ttgttgggta ctactttgtt gaacttggac gctaactacg ttgagactgc tagaactact 1200 atcgagtact tcattgactt catcgacaac gtttgtatgg acgagatcgc tagagaatcc 1260 cagagaaacg gtgttgctcc acaatctgag gctttgagaa agttggctgg tatcaagttc 1320 aagagaatca acttcaacaa ctcctccgag tacatcgaga actggaactt gcagaacaga 1380 aggcagagaa ctggtttcgt tttccacaag ccaaacatct tcccttactc cgcttcattc 1440 actttgaaca gatctcagcc aatgcacgac aacttgatgg gtactatgtg gttgaacgct 1500 ggttccgaga ttcaggttgc tggtttcgat tactcctgtg ctttgaacgc tccagctaac 1560 attcaacagt tcgagcacat cgttcagttg cgtagagctt tgactactgc tactatcact 1620 ttgttgccag acgctgagag attctcattc ccaagagtta tcaactccgc tgacggtgct 1680 actacatggt tcttcaaccc aatcatcctt agaccaaaca acgttgaggt tgagttcttg 1740 ttgaacggtc agatcatcaa cacttaccag gctagattcg gtactattat cgctagaaac 1800 ttcgacacta tcagattgtc cttccagttg atgaggccac caaacatgac tccagctgtt 1860 aacgctttgt tcccacaagc tcaaccattc caacaccacg ctactgttgg tttgactttg 1920 agaatcgagt ccgctgtttg tgagtccgtt ttggctgatg ctaacgagac tttgttggct 1980 aacgttactg ctgttagaca agagtacgct atcccagttg gtccagtttt tccaccaggt 2040 atgaactgga ctgagttgat cactaactac tccccatcca gagaggacaa cttgcagaga 2100 gtttcactg ttgcttccat cagatccatg ttgatcaagc tcgagccgcg gcggccgcca 2160 gcttacgtag aacaaaaact catctcagaa gaggatctga atagcgccgt cgaccatcat 2220 catcatcatc attgagtttg tagccttaga catgactgtt cctcagttca agttgggcac 2280 ttacgagaag accggtcttg ctagattcta atcaagagga tgtcagaatg ccatttgcct 2340 gagagatgca ggcttcattt ttgatacttt tttatttgta acctatatag tataggattt 2400 tttttgtcat tttgtttctt ctcgtacgag cttgctcctg atcagcctat ctcgcagctg 2460 atgaatatct tgtggtaggg gtttgggaaa atcattcgag tttgatgttt ttcttggtat 2520 ttcccactcc tcttcagagt acagaagatt aagtgagacc ttcgtttgtg cggatccccc 2580 acacaccata gcttcaaaat gtttctactc cttttttact cttccagatt ttctcggact 2640 ccgcgcatcg ccgtaccact tcaaaacacc caagcacagc atactaaatt ttccctcttt 2700 cttcctctag ggtgtcgtta attacccgta ctaaaggttt ggaaaagaaa aaagagaccg 2760 cctcgtttct ttttcttcgt cgaaaaaggc aataaaaatt tttatcacgt ttctttttct 2820 tgaaattttt ttttttagtt tttttctctt tcagtgacct ccattgatat ttaagttaat 2880 aaacggtctt caatttctca agtttcagtt tcatttttct tgttctatta caactttttt 2940 tacttcttgt tcattagaaa gaaagcatag caatctaatc taaggggcgg tgttgacaat 3000 taatcatcgg catagtatat cggcatagta taatacgaca aggtgaggaa ctaaaccatg 3060 gccaagttga ccagtgccgt tccggtgctc accgcgcgcg acgtcgccgg agcggtcgag 3120 ttctggaccg accggctcgg gttctcccgg gacttcgtgg aggacgactt cgccggtgtg 3180 gtccgggacg acgtgaccct gttcatcagc gcggtccagg accaggtggt gccggacaac 3240 accctggcct gggtgtgggt gcgcggcctg gacgagctgt acgccgagtg gtcggaggtc 3300 gtgtccacga acttccggga cgcctccggg ccggccatga ccgagatcgg cgagcagccg 3360 tgggggcggg agttcgccct gcgcgacccg gccggcaact gcgtgcactt cgtggccgag 3420 gagcaggact gacacgtccg acggcggccc acgggtccca ggcctcggag atccgtcccc 3480 cttttccttt gtcgatatca tgtaattagt tatgtcacgc ttacattcac gccctccccc 3540 cacatccgct ctaaccgaaa aggaaggagt tagacaacct gaagtctagg tccctattta 3600 tttttttata gttatgttag tattaagaac gttatttata tttcaaattt ttcttttttt 3660 tctgtacaga cgcgtgtacg catgtaacat tatactgaaa accttgcttg agaaggtttt 3720 gggacgctcg aaggctttaa tttgcaagct ggagaccaac atgtgagcaa aaggccagca 3780 aaaggccagg aaccgtaaaa aggccgcgtt gctggcgttt ttccataggc tccgcccccc 3840 tgacgagcat cacaaaaatc gacgctcaag tcagaggtgg cgaaacccga caggactata 3900 aagataccag gcgtttcccc ctggaagctc cctcgtgcgc tctcctgttc cgaccctgcc 3960 gcttaccgga tacctgtccg cctttctccc ttcgggaagc gtggcgcttt ctcaatgctc 4020 acgctgtagg tatctcagtt cggtgtaggt cgttcgctcc aagctgggct gtgtgcacga 4080 accccccgtt cagcccgacc gctgcgcctt atccggtaac tatcgtcttg agtccaaccc 4140 ggtaagacac gacttatcgc cactggcagc agccactggt aacaggatta gcagagcgag 4200 gtatgtaggc ggtgctacag agttcttgaa gtggtggcct aactacggct acactagaag 4260 gacagtattt ggtatctgcg ctctgctgaa gccagttacc ttcggaaaaa gagttggtag 4320 ctcttgatcc ggcaaacaaa ccaccgctgg tagcggtggt ttttttgttt gcaagcagca 4380 gattacgcgc agaaaaaaag gatctcaaga agatcctttg atcttttcta cggggtctga 4440 cgctcagtgg aacgaaaact cacgttaagg gattttggtc atgagatc 4488 <210> 3 <211> 9985 <212> DNA <213> Artificial Sequence <220> <223> pPIC3.5K-CAU200 VP7 <400> 3 agatctaaca tccaaagacg aaaggttgaa tgaaaccttt ttgccatccg acatccacag 60 gtccattctc acacataagt gccaaacgca acaggagggg atacactagc agcagaccgt 120 tgcaaacgca ggacctccac tcctcttctc ctcaacaccc acttttgcca tcgaaaaacc 180 agcccagtta ttgggcttga ttggagctcg ctcattccaa ttccttctat taggctacta 240 acaccatgac tttattagcc tgtctatcct ggcccccctg gcgaggttca tgtttgttta 300 tttccgaatg caacaagctc cgcattacac ccgaacatca ctccagatga gggctttctg 360 agtgtggggt caaatagttt catgttcccc aaatggccca aaactgacag tttaaacgct 420 gtcttggaac ctaatatgac aaaagcgtga tctcatccaa gatgaactaa gtttggttcg 480 ttgaaatgct aacggccagt tggtcaaaaa gaaacttcca aaagtcgcca taccgtttgt 540 cttgtttggt attgattgac gaatgctcaa aaataatctc attaatgctt agcgcagtct 600 ctctatcgct tctgaacccc ggtgcacctg tgccgaaacg caaatgggga aacacccgct 660 ttttggatga ttatgcattg tctccacatt gtatgcttcc aagattctgg tgggaatact 720 gctgatagcc taacgttcat gatcaaaatt taactgttct aacccctact tgacagcaat 780 atataaacag aaggaagctg ccctgtctta aacctttttt tttatcatca ttattagctt 840 actttcataa ttgcgactgg ttccaattga caagcttttg attttaacga cttttaacga 900 caacttgaga agatcaaaaa acaactaatt attcgaagga tccatgtacg gtatcgagta 960 cactactatc ttgattttct tgatctccat catcttgttg aactacatct tgaagtccgt 1020 tactagaatc atggactaca tcatctacag attcttgttg atctccgttg ctttgttcgc 1080 tttgactaag gctcagaact acggtttgaa catcccaatc actggttcca tggacactgt 1140 ttactccaac tccactcaag aagaggtttt cttgacttcc actttgtgtt tgtactaccc 1200 aactgaggct tccactcaga tttctgacgg tgagtggaaa gaatccttgt cccagatgtt 1260 cttgactaag ggttggccaa ctggttccgt ttacttcaaa gagtactcca acatcgttga 1320 cttctccgtt gacccacagt tgtactgtga ctacaacttg gttttgatga agtacgacca 1380 gaacttggag ttggacatgt ctgagttggc tgacttgatc ttgaacgagt ggttgtgtaa 1440 cccaatggac atcactttgt actactacca gcaatccggt gagtccaaca agtggatttc 1500 tatgggttcc tcctgtactg ttaaggtttg tccattgaac actcagactt tgggtatcgg 1560 ttgtcagact acaaacgttg actccttcga gactgttgct gagaacgaga agttggctat 1620 cgttgacgtt gttgacggta tcaaccacaa gatcaacttg actactacta cttgtactat 1680 cagaaactgt aagaagttgg gtccaagaga gaacgttgct gttatccaag ttggtggttc 1740 caacgttttg gacatcactg ctgacccaac tacaaaccca cagatcgaga gaatgatgag 1800 agttaactgg aagagatggt ggcaggtttt ctacactatc gttgactaca tcaaccagat 1860 cgttcaggtt atgtccaaga gatccagatc cttgaactcc gctgctttct actacagagt 1920 tcatcatcat catcaccact aagcggccgc gaattaattc gccttagaca tgactgttcc 1980 tcagttcaag ttgggcactt acgagaagac cggtcttgct agattctaat caagaggatg 2040 tcagaatgcc atttgcctga gagatgcagg cttcattttt gatacttttt tatttgtaac 2100 ctatatagta taggattttt tttgtcattt tgtttcttct cgtacgagct tgctcctgat 2160 cagcctatct cgcagctgat gaatatcttg tggtaggggt ttgggaaaat cattcgagtt 2220 tgatgttttt cttggtattt cccactcctc ttcagagtac agaagattaa gtgagaagtt 2280 cgtttgtgca agcttatcga taagctttaa tgcggtagtt tatcacagtt aaattgctaa 2340 cgcagtcagg caccgtgtat gaaatctaac aatgcgctca tcgtcatcct cggcaccgtc 2400 accctggatg ctgtaggcat aggcttggtt atgccggtac tgccgggcct cttgcgggat 2460 atcgtccatt ccgacagcat cgccagtcac tatggcgtgc tgctagcgct atatgcgttg 2520 atgcaatttc tatgcgcacc cgttctcgga gcactgtccg accgctttgg ccgccgccca 2580 gtcctgctcg cttcgctact tggagccact atcgactacg cgatcatggc gaccacaccc 2640 gtcctgtgga tctatcgaat ctaaatgtaa gttaaaatct ctaaataatt aaataagtcc 2700 cagtttctcc atacgaacct taacagcatt gcggtgagca tctagacctt caacagcagc 2760 cagatccatc actgcttggc caatatgttt cagtccctca ggagttacgt cttgtgaagt 2820 gatgaacttc tggaaggttg cagtgttaac tccgctgtat tgacgggcat atccgtacgt 2880 tggcaaagtg tggttggtac cggaggagta atctccacaa ctctctggag agtaggcacc 2940 aacaaacaca gatccagcgt gttgtacttg atcaacataa gaagaagcat tctcgatttg 3000 cggatcaag tgttcaggag cgtactgatt ggacatttcc aaagcctgct cgtaggttgc 3060 aaccgatagg gttgtagagt gtgcaataca cttgcgtaca atttcaaccc ttggcaactg 3120 cacagcttgg ttgtgaacag catcttcaat tctggcaagc tccttgtctg tcatatcgac 3180 agccaacaga atcacctggg aatcaatacc atgttcagct tgagacagaa ggtctgaggc 3240 aacgaaatct ggatcagcgt atttatcagc aataactaga acttcagaag gcccagcagg 3300 catgtcaata ctacacaggg ctgatgtgtc attttgaacc atcatcttgg cagcagtaac 3360 gaactggttt cctggaccaa atattttgtc acacttagga acagtttctg ttccgtaagc 3420 catagcagct actgcctggg cgcctcctgc tagcacgata cacttagcac caaccttgtg 3480 ggcaacgtag atgacttctg gggtaagggt accatccttc ttaggtggag atgcaaaaac 3540 aatttctttg caaccagcaa ctttggcagg aacacccagc atcagggaag tggaaggcag 3600 aattgcggtt ccaccaggaa tatagaggcc aactttctca ataggtcttg caaaacgaga 3660 gcagactaca ccagggcaag tctcaacttg caacgtctcc gttagttgag cttcatggaa 3720 tttcctgacg ttatctatag agagatcaat ggctctctta acgttatctg gcaattgcat 3780 aagttcctct gggaaaggag cttctaacac aggtgtcttc aaagcgactc catcaaactt 3840 ggcagttagt tctaaaaggg ctttgtcacc attttgacga acattgtcga caattggttt 3900 gactaattcc ataatctgtt ccgttttctg gataggacga cgaagggcat cttcaatttc 3960 ttgtgaggag gccttagaaa cgtcaatttt gcacaattca atacgacctt cagaagggac 4020 ttctttaggt ttggattctt ctttaggttg ttccttggtg tatcctggct tggcatctcc 4080 tttccttcta gtgaccttta gggacttcat atccaggttt ctctccacct cgtccaacgt 4140 cacaccgtac ttggcacatc taactaatgc aaaataaaat aagtcagcac attcccaggc 4200 tatatcttcc ttggatttag cttctgcaag ttcatcagct tcctccctaa ttttagcgtt 4260 caacaaaact tcgtcgtcaa ataaccgttt ggtataagaa ccttctggag cattgctctt 4320 acgatcccac aaggtggctt ccatggctct aagacccttt gattggccaa aacaggaagt 4380 gcgttccaag tgacagaaac caacacctgt ttgttcaacc acaaatttca agcagtctcc 4440 atcacaatcc aattcgatac ccagcaactt ttgagttgct ccagatgtag cacctttata 4500 ccacaaaccg tgacgacgag attggtagac tccagtttgt gtccttatag cctccggaat 4560 agactttttg gacgagtaca ccaggcccaa cgagtaatta gaagagtcag ccaccaaagt 4620 agtgaataga ccatcggggc ggtcagtagt caaagacgcc aacaaaattt cactgacagg 4680 gaactttttg acatcttcag aaagttcgta ttcagtagtc aattgccgag catcaataat 4740 ggggattata ccagaagcaa cagtggaagt cacatctacc aactttgcgg tctcagaaaa 4800 agcataaaca gttctactac cgccattagt gaaacttttc aaatcgccca gtggagaaga 4860 aaaaggcaca gcgatactag cattagcggg caaggatgca actttatcaa ccagggtcct 4920 atagataacc ctagcgcctg ggatcatcct ttggacaact ctttctgcca aatctaggtc 4980 caaaatcact tcattgatac cattattgta caacttgagc aagttgtcga tcagctcctc 5040 aaattggtcc tctgtaacgg atgactcaac ttgcacatta acttgaagct cagtcgattg 5100 agtgaacttg atcaggttgt gcagctggtc agcagcatag ggaaacacgg cttttcctac 5160 caaactcaag gaattatcaa actctgcaac acttgcgtat gcaggtagca agggaaatgt 5220 catacttgaa gtcggacagt gagtgtagtc ttgagaaatt ctgaagccgt atttttatta 5280 tcagtgagtc agtcatcagg agatcctcta cgccggacgc atcgtggccg acctgcaggg 5340 gggggggggg cgctgaggtc tgcctcgtga agaaggtgtt gctgactcat accaggcctg 5400 aatcgcccca tcatccagcc agaaagtgag ggagccacgg ttgatgagag ctttgttgta 5460 ggtggaccag ttggtgattt tgaacttttg ctttgccacg gaacggtctg cgttgtcggg 5520 aagatgcgtg atctgatcct tcaactcagc aaaagttcga tttattcaac aaagccgccg 5580 tcccgtcaag tcagcgtaat gctctgccag tgttacaacc aattaaccaa ttctgattag 5640 aaaaactcat cgagcatcaa atgaaactgc aatttattca tatcaggatt atcaatacca 5700 tatttttgaa aaagccgttt ctgtaatgaa ggagaaaact caccgaggca gttccatagg 5760 atggcaagat cctggtatcg gtctgcgatt ccgactcgtc caacatcaat acaacctatt 5820 aatttcccct cgtcaaaaat aaggttatca agtgagaaat caccatgagt gacgactgaa 5880 tccggtgaga atggcaaaag cttatgcatt tctttccaga cttgttcaac aggccagcca 5940 ttacgctcgt catcaaaatc actcgcatca accaaaccgt tattcattcg tgattgcgcc 6000 tgagcgagac gaaatacgcg atcgctgtta aaaggacaat tacaaacagg aatcgaatgc 6060 aaccggcgca ggaacactgc cagcgcatca acaatatttt cacctgaatc aggatattct 6120 tctaatacct ggaatgctgt tttcccgggg atcgcagtgg tgagtaacca tgcatcatca 6180 ggagtacgga taaaatgctt gatggtcgga agaggcataa attccgtcag ccagtttagt 6240 ctgaccatct catctgtaac atcattggca acgctacctt tgccatgttt cagaaacaac 6300 tctggcgcat cgggcttccc atacaatcga tagattgtcg cacctgattg cccgacatta 6360 tcgcgagccc atttataccc atataaatca gcatccatgt tggaatttaa tcgcggcctc 6420 gagcaagacg tttcccgttg aatatggctc ataacacccc ttgtattact gtttatgtaa 6480 gcagacagtt ttattgttca tgatgatata tttttatctt gtgcaatgta acatcagaga 6540 ttttgagaca caacgtggct ttcccccccc cccctgcagg tcggcatcac cggcgccaca 6600 ggtgcggttg ctggcgccta tatcgccgac atcaccgatg gggaagatcg ggctcgccac 6660 ttcgggctca tgagcgcttg tttcggcgtg ggtatggtgg caggccccgt ggccggggga 6720 ctgttgggcg ccatctcctt gcatgcacca ttccttgcgg cggcggtgct caacggcctc 6780 aacctactac tgggctgctt cctaatgcag gagtcgcata agggagagcg tcgagtatct 6840 atgattggaa gtatgggaat ggtgataccc gcattcttca gtgtcttgag gtctcctatc 6900 agattatgcc caactaaagc aaccggagga ggagatttca tggtaaattt ctctgacttt 6960 tggtcatcag tagactcgaa ctgtgagact atctcggtta tgacagcaga aatgtccttc 7020 ttggagacag taaatgaagt cccaccaata aagaaatcct tgttatcagg aacaaacttc 7080 ttgtttcgaa ctttttcggt gccttgaact ataaaatgta gagtggatat gtcgggtagg 7140 aatggagcgg gcaaatgctt accttctgga ccttcaagag gtatgtaggg tttgtagata 7200 ctgatgccaa cttcagtgac aacgttgcta tttcgttcaa accattccga atccagagaa 7260 atcaaagttg tttgtctact attgatccaa gccagtgcgg tcttgaaact gacaatagtg 7320 tgctcgtgtt ttgaggtcat ctttgtatga ataaatctag tctttgatct aaataatctt 7380 gacgagccaa ggcgataaat acccaaatct aaaactcttt taaaacgtta aaaggacaag 7440 tatgtctgcc tgtattaaac cccaaatcag ctcgtagtct gatcctcatc aacttgaggg 7500 gcactatctt gttttagaga aatttgcgga gatgcgatat cgagaaaaag gtacgctgat 7560 tttaaacgtg aaatttatct caagatctct gcctcgcgcg tttcggtgat gacggtgaaa 7620 acctctgaca catgcagctc ccggagacgg tcacagcttg tctgtaagcg gatgccggga 7680 gcagacaagc ccgtcagggc gcgtcagcgg gtgttggcgg gtgtcggggc gcagccatga 7740 cccagtcacg tagcgatagc ggagtgtata ctggcttaac tatgcggcat cagagcagat 7800 tgtactgaga gtgcaccata tgcggtgtga aataccgcac agatgcgtaa ggagaaaata 7860 ccgcatcagg cgctcttccg cttcctcgct cactgactcg ctgcgctcgg tcgttcggct 7920 gcggcgagcg gtatcagctc actcaaaggc ggtaatacgg ttatccacag aatcagggga 7980 taacgcagga aagaacatgt gagcaaaagg ccagcaaaag gccaggaacc gtaaaaaggc 8040 cgcgttgctg gcgtttttcc ataggctccg cccccctgac gagcatcaca aaaatcgacg 8100 ctcaagtcag aggtggcgaa acccgacagg actataaaga taccaggcgt ttccccctgg 8160 aagctccctc gtgcgctctc ctgttccgac cctgccgctt accggatacc tgtccgcctt 8220 tctcccttcg ggaagcgtgg cgctttctca atgctcacgc tgtaggtatc tcagttcggt 8280 gtaggtcgtt cgctccaagc tgggctgtgt gcacgaaccc cccgttcagc ccgaccgctg 8340 cgccttatcc ggtaactatc gtcttgagtc caacccggta agacacgact tatcgccact 8400 ggcagcagcc actggtaaca ggattagcag agcgaggtat gtaggcggtg ctacagagtt 8460 cttgaagtgg tggcctaact acggctacac tagaaggaca gtatttggta tctgcgctct 8520 gctgaagcca gttaccttcg gaaaaagagt tggtagctct tgatccggca aacaaaccac 8580 cgctggtagc ggtggttttt ttgtttgcaa gcagcagatt acgcgcagaa aaaaaggatc 8640 tcaagaagat cctttgatct tttctacggg gtctgacgct cagtggaacg aaaactcacg 8700 ttaagggatt ttggtcatga gattatcaaa aaggatcttc acctagatcc ttttaaatta 8760 aaaatgaagt tttaaatcaa tctaaagtat atatgagtaa acttggtctg acagttacca 8820 atgcttaatc agtgaggcac ctatctcagc gatctgtcta tttcgttcat ccatagttgc 8880 ctgactcccc gtcgtgtaga taactacgat acgggagggc ttaccatctg gccccagtgc 8940 tgcaatgata ccgcgagacc cacgctcacc ggctccagat ttatcagcaa taaaccagcc 9000 agccggaagg gccgagcgca gaagtggtcc tgcaacttta tccgcctcca tccagtctat 9060 taattgttgc cgggaagcta gagtaagtag ttcgccagtt aatagtttgc gcaacgttgt 9120 tgccattgct gcaggcatcg tggtgtcacg ctcgtcgttt ggtatggctt cattcagctc 9180 cggttcccaa cgatcaaggc gagttacatg atcccccatg ttgtgcaaaa aagcggttag 9240 ctccttcggt cctccgatcg ttgtcagaag taagttggcc gcagtgttat cactcatggt 9300 tatggcagca ctgcataatt ctcttactgt catgccatcc gtaagatgct tttctgtgac 9360 tggtgagtac tcaaccaagt cattctgaga atagtgtatg cggcgaccga gttgctcttg 9420 cccggcgtca acacgggata ataccgcgcc acatagcaga actttaaaag tgctcatcat 9480 tggaaaacgt tcttcggggc gaaaactctc aaggatctta ccgctgttga gatccagttc 9540 gatgtaaccc actcgtgcac ccaactgatc ttcagcatct tttactttca ccagcgtttc 9600 tgggtgagca aaaacaggaa ggcaaaatgc cgcaaaaaag ggaataaggg cgacacggaa 9660 atgattgaata ctcatactct tcctttttca atattattga agcatttatc agggttattg 9720 tctcatgagc ggatacatat ttgaatgtat ttagaaaaat aaacaaatag gggttccgcg 9780 cacatttccc cgaaaagtgc cacctgacgt ctaagaaacc attattatca tgacattaac 9840 ctataaaaat aggcgtatca cgaggccctt tcgtcttcaa gaattaattc tcatgtttga 9900 cagcttatca tcgataagct gactcatgtt ggtattgtga aatagacgca gatcgggaac 9960 actgaaaaat aacagttatt attcg 9985 <210> 4 <211> 2694 <212> DNA <213> Artificial Sequence <220> <223> CAU200 VP2co <400> 4 gaattcatgg cttacagaaa gagaggtgct aagagagagg acttgccaca acagaacgag 60 agattgcaag agaaagagat cgagaacaac actgacgtta ctatggaaaa caagaacaag 120 aacaaaaaca acaatagaaa gcagcagttg tccgacaagg ttttgtccca gaaagaagag 180 atcatcactg acgttcagga cgacatcaag atcgctgacg aagttaagaa gtcctccaaa 240 gaagagtcca agcagttgtt ggagatcttg aaaacaaaag aggaccacca gaaagaggtt 300 cagtacgaga tcttgcaaaa gactatccca actttcgagc caaaagagtc catcttgaag 360 aagttggagg acatcaagcc agagcaggct aagaaacaga tgaagttgtt cagaatcttc 420 gagccaagac agttgccaat ctacagagct aacggtgaga aagaattgag aaacagatgg 480 tactggaagt tgaagaaaga cactttgcca gacggtgact acgacgttag agagtacttc 540 ttgaacttgt acgaccagat cttgatcgag atgccagact acttgttgtt gaaggacatg 600 gctgttgaga acaagaactc cagagatgct ggtaaggttg ttgactccga gactgctaga 660 atctgtgacg ctattttcca ggacgaagag actgagggtg ttattagaag attcattgct 720 gacatgagac agcaggttca ggctgacaga aacatcgtta actacccatc catcttgcac 780 ccaatcgacc acgctttcaa cgagtacttt ttgaaccacc agttggttga gccattgaac 840 aacgagatca tcttcaacta catccctgag agaatcagaa acgacgttaa ttacatcttg 900 aacatggaca tgaacttgcc atccactgct agatatatca gaccaaactt gttgcaggac 960 agattgaact tgcacgacaa cttcgaatcc ttgtggga ctatcactac ttccaactac 1020 atcttggcta gatccgttgt tccagacttg aaagagaaag agttggtttc cactgaggct 1080 cagatccaga agatgtccca agacttgcaa ttggaggctt tgactatcca gtccgagact 1140 caattcttgg ctggtattaa ctcccaggct gctaacgact gtttcaagac tttgatcgct 1200 gctatgttgt cccagagaac tatgtccttg gacttcgtta ctacaaacta catgtccttg 1260 atctccggta tgtggttgtt gactgttatc ccaaacgaca tgttcttgag agaatccttg 1320 gttgcttgtg agttggctat catcaacact atcgtttacc cagctttcgg tatgcagaga 1380 atgcactaca gaaacggtga cccacaaact ccattccaga ttgctgagca gcagatccag 1440 aacttccaag ttgctaactg gttgcacttc atcaacaaca acagattcag acaggttgtt 1500 atcgacggtg ttttgaacca gactttgaac gacaacatca gaaacggtca ggttatcaac 1560 cagttgatgg aagctttgat gcagttgtcc agacagcagt tcccaactat gccagttgac 1620 tacaagagat ccatccagag aggtatcttg ttgttgtcca acagattggg tcagttggtt 1680 gacttgacta gacttttgtc ctacaactac gagactttga tggcttgtat cactatgaac 1740 atgcagcacg ttcagacttt gactactgag agattgcagt tgacttccgt tacttccttg 1800 tgtatgttga tcggtaacac tactgttatt ccatccccac agactttgtt ccactactac 1860 aacgttaatg ttaacttcca ctccaactac aacgagagaa tcaacgacgc tgttgctatc 1920 atcactgctg ctaatagatt gaacttgtac caaaagaaga tgaagtccat cgttgaggat 1980 ttcttgaaga gattgcagat cttcgacgtt ccaagagttc cagacgacca gatgtacaga 2040 ttgagagaca gattgagact tttgccagtt gagagaagaa gattggacat cttcaacttg 2100 atcttgatga acatggaaca gatcgagaga gcttccgaca agattgctca gggtgttatc 2160 attgcttaca gagatatgca gttggagcgt gatgagatgt acggtttcgt taacattgct 2220 agaaacttgg acggttacca gcagatcaac ttggaagagt tgatgagaac tggtgactac 2280 ggtcagatca ctaacatgtt gttgaacaac cagccagttg ctttggttgg tgctttgcct 2340 ttcgttactg actcctccgt tatctccttg atcgctaagt tggacgctac tgttttcgct 2400 cagatcgtta agttgagaaa ggttgacact ttgaagccaa tcttgtacaa aatcaactcc 2460 gactccaacg acttctactt ggttgctaac tacgactgga tcccaacttc cactactaag 2520 gtttacaagc aggttccaca gccattcgac ttcagagctt ctatgcacat gttgacttcc 2580 aacttgactt tcactgttta ctccgacttg ttgtccttcg tttccgctga cactgttgag 2640 cctattaacg ctatcgcttt cgacaacatg agaatcatga acgagttgct cgag 2694 <210> 5 <211> 1203 <212> DNA <213> Artificial Sequence <220> <223> CAU200 VP6co <400> 5 gaattcatgg aagttttgta ctcattgtcc aagactttga aggacgctag agacaagatc 60 gttgagggta ctttgtactc caacgtttcc gacttgatcc agcagttcaa ccagatgatc 120 gttactatga acggtaacga cttccagact ggtggtatcg gtaacttgcc aatcagaaac 180 tggactttcg acttcggttt gttggtact actttgttga acttggacgc taactacgtt 240 gagactgcta gaactactat cgagtacttc attgacttca tcgacaacgt ttgtatggac 300 gagatcgcta gagaatccca gagaaacggt gttgctccac aatctgaggc tttgagaaag 360 ttggctggta tcaagttcaa gagaatcaac ttcaacaact cctccgagta catcgagaac 420 tggaacttgc agaacagaag gcagagaact ggtttcgttt tccacaagcc aaacatcttc 480 ccttactccg cttcattcac tttgaacaga tctcagccaa tgcacgacaa cttgatgggt 540 actatgtggt tgaacgctgg ttccgagatt caggttgctg gtttcgatta ctcctgtgct 600 ttgaacgctc cagctaacat tcaacagttc gagcacatcg ttcagttgcg tagagctttg 660 actactgcta ctatcacttt gttgccagac gctgagagat tctcattccc aagagttatc 720 aactccgctg acggtgctac tacatggttc ttcaacccaa tcatccttag accaaacaac 780 gttgaggttg agttcttgtt gaacggtcag atcatcaaca cttaccaggc tagattcggt 840 actattatcg ctagaaactt cgacactatc agattgtcct tccagttgat gaggccacca 900 aacatgactc cagctgttaa cgctttgttc ccacaagctc aaccattcca acaccacgct 960 actgttggtt tgactttgag aatcgagtcc gctgtttgtg agtccgtttt ggctgatgct 1020 aacgagactt tgttggctaa cgttactgct gttagacaag agtacgctat cccagttggt 1080 ccagtttttc caccaggtat gaactggact gagttgatca ctaactactc cccatccaga 1140 gaggacaact tgcagagagt tttcactgtt gcttccatca gatccatgtt gatcaagctc 1200 gag 1203 <210> 6 <211> 990 <212> DNA <213> Artificial Sequence <220> <223> CAU200 VP7co <400> 6 gaattcatgt acggtatcga gtacactact atcttgattt tcttgatctc catcatcttg 60 ttgaactaca tcttgaagtc cgttactaga atcatggact acatcatcta cagattcttg 120 ttgatctccg ttgctttgtt cgctttgact aaggctcaga actacggttt gaacatccca 180 atcactggtt ccatggacac tgtttactcc aactccactc aagaagaggt tttcttgact 240 tccactttgt gtttgtacta cccaactgag gcttccactc agatttctga cggtgagtgg 300 aaagaatcct tgtcccagat gttcttgact aagggttggc caactggttc cgtttacttc 360 aaagagtact ccaacatcgt tgacttctcc gttgacccac agttgtactg tgactacaac 420 ttggttttga tgaagtacga ccagaacttg gagttggaca tgtctgagtt ggctgacttg 480 atcttgaacg agtggttgtg taacccaatg gacatcactt tgtactacta ccagcaatcc 540 ggtgagtcca acaagtggat ttctatgggt tcctcctgta ctgttaaggt ttgtccattg 600 aacactcaga ctttgggtat cggttgtcag actacaaacg ttgactcctt cgagactgtt 660 gctgagaacg agaagttggc tatcgttgac gttgttgacg gtatcaacca caagatcaac 720 ttgactacta ctacttgtac tatcagaaac tgtaagaagt tgggtccaag agagaacgtt 780 gctgttatcc aagttggtgg ttccaacgtt ttggacatca ctgctgaccc aactacaaac 840 ggagttaac atcgttgact acatcaacca gatcgttcag gttatgtcca agagatccag atccttgaac 960 tccgctgctt tctactacag agttctcgag 990 <210> 7 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> AOX1 primer <400> 7 gcaaatggca ttctgacatc c 21 <210> 8 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> VP2 primer <400> 8 ccaggacgaa gagactgagg 20 <210> 9 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> VP6 primer <400> 9 caacagttcg agcacatcgt 20 <210> 10 <211> 23 <212> DNA <213> Artificial Sequence <220> <223> V7 primer <400> 10 cagttgtact gtgactacaa ctt 23

Claims (9)

a) 로타바이러스 구조 단백질이 발현되도록 효모 세포를 형질전환하는 단계;
b) 상기 형질전환된 효모 세포를 메탄올이 첨가된 배지에서 배양하는 단계;
c) 상기 배양된 효모 세포를 용해시켜 세포 용해물을 얻는 단계; 및
d) 상기 세포 용해물로부터 로타바이러스의 바이러스 유사입자를 분리 및 정제하는 단계를 포함하는 로타바이러스(Rotavirus)의 바이러스 유사입자(virus-like particle, VLP)의 생산 및 정제방법으로서,
상기 단계 a)에서의 효모는 피키아 파스토리스(Pichia pastoris)인 것을 특징으로 하고;
상기 단계 b)는 1 내지 1.5% 농도의 메탄올을 첨가하여, 24 내지 48시간 배양하고;
상기 단계 c)는 Tris-HCl, NaCl, CaCl2, EDTA(ethylenediaminetetraacetic acid), PMSF(phenylmethanesulfonyl fluoride), glycerol, 및 Tween20을 함유하는 세포파쇄 완충액으로 용해시키는 것을 특징으로 하는, 생산 및 정제방법.
a) transforming yeast cells to express a rotavirus structural protein;
b) culturing the transfected yeast cells in a medium supplemented with methanol;
c) dissolving the cultured yeast cells to obtain a cell lysate; And
and d) separating and purifying virus-like particles of rotavirus from the cell lysate, wherein the virus-like particle (VLP)
Wherein the yeast in step a) is Pichia pastoris ;
The step b) is carried out by adding methanol at a concentration of 1 to 1.5% and culturing for 24 to 48 hours;
Wherein said step c) is dissolved in a cell disruption buffer containing Tris-HCl, NaCl, CaCl 2 , ethylenediaminetetraacetic acid (EDTA), PMSF, glycerol, and Tween 20.
제1항에 있어서,
상기 단계 a)는 서열번호 1로 표시되는 pPIC6-CAU200 VP2 벡터, 서열번호 2로 표시되는 pPICZ-CAU200 VP6 벡터, 및 서열번호 3으로 표시되는 pPIC3.5K-CAU200 VP7 벡터로 효모 세포를 형질전환하는 것을 특징으로 하는, 생산 및 정제방법.
The method according to claim 1,
The above step a) is a step of transforming yeast cells with the pPIC6-CAU200 VP2 vector of SEQ ID NO: 1, the pPICZ-CAU200 VP6 vector of SEQ ID NO: 2, and the pPIC3.5K-CAU200 VP7 vector of SEQ ID NO: 3 &Lt; / RTI &gt;
삭제delete 삭제delete 삭제delete 삭제delete 제1항의 방법에 의해 생산 및 정제된 로타바이러스(Rotavirus)의 바이러스 유사입자(virus-like particle).
A virus-like particle of Rotavirus produced and purified by the method of claim 1.
제7항에 있어서,
상기 바이러스 유사입자는 로타바이러스 구조 단백질인 VP2, VP6, 및 VP7을 동시에 발현하는 것을 특징으로 하는, 바이러스 유사입자.
8. The method of claim 7,
Wherein said virus-like particle simultaneously expresses the rotavirus structural proteins VP2, VP6, and VP7.
제7항의 로타바이러스(Rotavirus)의 바이러스 유사입자(virus-like particle)를 포함하는, 면역원성 조성물. An immunogenic composition comprising the virus-like particle of Rotavirus of claim 7.
KR1020150136207A 2015-09-25 2015-09-25 Method for Producing and Purifying Virus-Like Particle of Rotavirus using Yeast strain Expired - Fee Related KR101818816B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020150136207A KR101818816B1 (en) 2015-09-25 2015-09-25 Method for Producing and Purifying Virus-Like Particle of Rotavirus using Yeast strain

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020150136207A KR101818816B1 (en) 2015-09-25 2015-09-25 Method for Producing and Purifying Virus-Like Particle of Rotavirus using Yeast strain

Publications (2)

Publication Number Publication Date
KR20170037708A KR20170037708A (en) 2017-04-05
KR101818816B1 true KR101818816B1 (en) 2018-01-17

Family

ID=58587175

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020150136207A Expired - Fee Related KR101818816B1 (en) 2015-09-25 2015-09-25 Method for Producing and Purifying Virus-Like Particle of Rotavirus using Yeast strain

Country Status (1)

Country Link
KR (1) KR101818816B1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101883148B1 (en) * 2017-10-11 2018-07-30 롯데푸드 주식회사 Novel lactobacillus plantarum LRCC5310 having inhibitory activity against Rota virus and Exopolysaccharide derived from the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100812637B1 (en) 2006-10-24 2008-03-13 주식회사 단바이오텍 Recombinant canine rotavirus JP4 protein comprising antigenic determinants and antibodies thereto
KR101316102B1 (en) 2010-04-30 2013-10-11 중앙대학교 산학협력단 Method for Preparing Recombinant Antigen Complex Using Rotavirus Nanoparticle

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100812637B1 (en) 2006-10-24 2008-03-13 주식회사 단바이오텍 Recombinant canine rotavirus JP4 protein comprising antigenic determinants and antibodies thereto
KR101316102B1 (en) 2010-04-30 2013-10-11 중앙대학교 산학협력단 Method for Preparing Recombinant Antigen Complex Using Rotavirus Nanoparticle

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
W.A.Rodriguez-Limans, et al., Microbial Cell Factories, 2011, vol 10(33).*

Also Published As

Publication number Publication date
KR20170037708A (en) 2017-04-05

Similar Documents

Publication Publication Date Title
US6287571B1 (en) Replication-defective adenovirus human type 5 recombinant as a vaccine carrier
DK2432884T3 (en) Antibiotic-free PLASMID
KR20200078512A (en) Gene therapy for lysosomal disorders
US12305190B2 (en) Vesicular stomatitis virus and virus rescue system
CN112226444B (en) Respiratory syncytial virus full-length prefusion glycoprotein nucleotide sequence, recombinant adenovirus vector and its application products
CN104694452A (en) Recombinant bacillus subtilis of high-yield pullulanase and construction method thereof
CN107988258B (en) A kind of Zika virus vaccine based on chimpanzee adenovirus vector and preparation method thereof
US20040053216A1 (en) DNA vaccines against hantavirus infections
KR101077330B1 (en) Dna vaccines against hantavirus infections
US20220090136A1 (en) Sin nombre virus full-length m segment-based dna vaccines
WO1996039178A1 (en) A replication-defective adenovirus human type 5 recombinant as a vaccine carrier
KR101818816B1 (en) Method for Producing and Purifying Virus-Like Particle of Rotavirus using Yeast strain
CN113355295A (en) Recombinant oncolytic newcastle disease virus expressing human GM-CSF and application thereof
CN112852759A (en) Recombinant rabies virus of chimeric canine parvovirus VP2 gene and application thereof
CN109957551B (en) Recombinant vaccinia virus expressing human beta-defensin 2 and application thereof
CN111214496A (en) Application of recombinant oncolytic virus in preparation of pharmaceutical composition for treating lymphoma
CN102051379A (en) Recombinant herpes simplex virus (HSV) genetic operation system and application thereof
KR102422842B1 (en) Compositon for regulating translation of RNA using CRISPRi
CN114606218A (en) Coronavirus neutralizing effector protein and application thereof
CN114606219A (en) Coronavirus neutralizing effect protein and application thereof
CN114934056A (en) mRNA vaccine based on novel mutant strain of coronavirus Onckrozen
CN111549048A (en) Expression plasmid for bacterial asd gene balance lethal system and application thereof
CN113234692B (en) Infectious clone containing rabies virus glycoprotein and application
CN114736287B (en) Hypoallergenic α-lactalbumin and its preparation method and application
CN116650667A (en) Application of gp96 mRNA packaged in nanoliposomes in the preparation of products for the treatment of nonalcoholic fatty liver

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U11-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

St.27 status event code: A-5-5-R10-R13-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

St.27 status event code: A-5-5-R10-R13-asn-PN2301

PR1001 Payment of annual fee

Fee payment year number: 4

St.27 status event code: A-4-4-U10-U11-oth-PR1001

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PR1001 Payment of annual fee

Fee payment year number: 5

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 6

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PC1903 Unpaid annual fee

Not in force date: 20240110

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

St.27 status event code: A-5-5-R10-R13-asn-PN2301

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240110

St.27 status event code: N-4-6-H10-H13-oth-PC1903

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000